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Abstract
CD44 is a cell surface glycoprotein (mol. wt. =85-95 kDa) which has
been implicated in lymphocyte-HEV interactions and the process of
lymphocyte homing.

CD44 is a complex glycoprotein which undergoes

extensive alternative splicing to generate various CD44 isoforms. CD44
functions include the delivery of an activation signal to T-cells, binding to
hyaluronate, mediation of lymphocyte homing, and the spread of metastatic
cells. CD44 has been particularly implicated in the dissemination of nonHodgkin's lymphoma and as such may serve as a useful prognostic marker
of disease progression. CD44 measurement in serum may provide a rapid,
inexpensive and relatively non-invasive prognostic marker for NHL.
Commercial ELISA systems have been developed for such a purpose
and were assessed as part of this study. Two assays were evaluated but
both were found to be unsatisfactory. The lack of efficacy of the assays led
to the development of an 'in-house' ELISA system.

The development of

such a system requires CD44 antigen, which despite several approaches to
the various manufacturers, proved impossible to obtain.

Cloned CD44

cDNA was therefore used to generate antigen by recombinant DNA
methods. CD44 cDNA was subcloned into the pTrcHis2 expression vector .
CD44 protein expression was induced by IPTG and purified by affinity
chromatography. The presence of the protein was confirmed by SDS-PAGE
and western blot analysis. The protein was quantified using a Hitachi 911
analyser.
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Introduction

1. Introduction
The mammalian immune system requires numerous type-specific
interactions to maintain its normal function. The interaction of lymphocytes
with high endothelial venules (HEV), specialised endothelial cells designed
to support the extravasation of circulating lymphocytes from the blood is a
well characterised heterotypic cell-cell interaction.
Lymphocyte-HEV interactions exhibit a remarkable tissue specificity,
controlling the migration and tissue distribution of lymphocyte subsets.

In

humans, a family of lymphocyte surface glycoproteins ranging in molecular
weight

from

85-95

kDa

have

been

implicated

in

interactions and the process of lymphocyte homing (Picker

lymphocyte-HEV
1989). This

class of glycoprotein has been termed the Cluster of Differentiation 44 or
CD44. Comparative amino acid sequence analysis has revealed CD44 to
be closely related or indentical to several other independently studied cell
surface markers including the extracellular matrix receptor III (ECMRIII;
Wayner and Carter 1987), phagocytic glycoprotein-1 (Pgp-1; Isacke M
1986), the hyaluronate receptor (Alho and Underhill, 1989), p80 (Haynes ^
al., 1983), p85 (Letarte Mai-, 1985), antigens of the monoclonal antibody
F-10-44-2 (Dalchau M aj., 1980), Hermes-1 (Jalkanen MaJ., 1986), CDw44
(Stamenkovic M^-, 1989) and gp®° (Jalkanen Maj., 1988).

1.1. Origin of CD44
Jaikanen et aj., (1988) described a lymphocyte surface glycoprotein
involved in lymphocyte binding to lymph node HEV, using a monoclonal
antibody (mAb) of the Hermes series (Jaikanen ^^.,1986) to define an 8595 kDa antigen involved in the recognition of lymph node, mucosal and
synovial HEV adhesion events.

The antigen, termed gp®°, due to its

approximate molecular weight of 90 kDa, could be blocked by the Hermes-1
antibody, inhibiting lymphocyte binding to lymph node or mucosal HEV,
indicating a possible role for the protein in lymphocyte interactions.

A polyclonal anti-gp^° serum, produced against highly purified Hermes-1
antigen from a mucosal HEV-specific cell line was found to inhibit the 3
classes of lymphocyte recognition. In addition, the mAb Mel-14, was found
to specifically inhibit human lymphocyte binding to lymph node HEV and the
mAb Hermes-3, to specifically block binding of lymphocytes to mucosal HEV.
These results suggest a common mechanism involving the gp^° or Hermes-1
antigen that is associated with at least three functionally independent
recognition systems that direct lymphocyte homing.

1.2. Structure of CD44
Goldstein ^ ^., (1989) related the structure of gp®° to that of cartilage
proteoglycan and link proteins. Proteoglycan monomers and link protein
form a ternary complex with Hyaluronic Acid (HA) in cartilage. Link protein is

comprised of 3 disulphide bonded loops, termed A, B and B’ respectively. In
chicken link protein, the B and B’ domains are encoded by a single exon.
This region was found to be closely related to the corresponding regions of
gp^° (CD44). In addition, similar sequences were present in two N-terminal
globular domains of rat cartilage proteoglycan core protein. However, CD44
glycoprotein differed in that it contained a single non-repeating unit in
contrast to link protein and proteoglycan core monomer sequences.
From observations (Goldstein Mai-, 1989) based on cDNA isolation of a
gp90^®^^®® receptor from a mucosal HEV-binding cell line KCA, it was
predicted that the proximal extracellular domain

may characterise a

structurally significant region. The fact that this region is hydrophilic and
antigenic implies it is probably on an external surface.
It was also shown that mAb Hermes - 3 recognised an epitope in this region,
suggesting it may be important for binding of CD44 to mucosal vascular
addressin, a cell surface endothelial antigen involved in lymphocyte
interactions with HEV.
The distal region of the extracellular domain was found to be
homologous to link protein and proteoglycan monomer subregions.

The

disulphide regions depicted in this area were proposed based on known
disulphide bonds in link protein and proteoglycan monomer.

In this

homologous region, two central cysteine molecules are paired to form the
apex of a loop (Cys 76 - Cys 96) and two additional cysteine molecules for
another disulphide link (Cys 52 - Cys 117) (see Fig. 1.1).
The homologous region is then flanked by two additional cysteines at
positions 27 and 128, which may create a third disulphide bond.

Figure 1.1 Predicted Secondary Structure of CD44
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Potential sites for Chondroitin Sulphate Linkage
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S—

Disulphide bonds between Cysteine molecules
(Goldstein
.,1989)

Southern blot analysis of the KCA genome indicated the receptor may be
present at a low copy number.

mapped to the short arm of

chromosome 11 by both Southern blot and immunoflouresence.

Northern

blot analysis revealed RNA bands at 1.5, 2.2 and 4.5 kb in cell lines that
expressed gp90^®^^®® regardless of HEV-binding specificity, suggesting that
a common gp90^®^^®® core protein may exist which may be utilised by both
lymph node and mucosal HEV-binding cells.

Similarly, Stamenkovic ^ a}., (1989) also associated CD44 with the
cartilage link protein family.

It was found that the amino terminal domain

shared approximately 30% homology with chicken and rat cartilage link
proteins and rat proteoglycan core protein. In addition, Stamenkovic e\ aj.,
(1989) suggested a role for CD44 in adhesion. Since proteoglycans consist
of glycosaminoglycan chains covalently bound to a core protein. Cartilage
proteoglycan core protein binds HA to form large aggregates, implying a
possible role for CD44 in matrix interactions.

Biochemical analysis of CDw44 (Stamenkovic et af., 1989) from
transfected COS cells and cell lines characterised two distinct forms of
CDw44:
(i) an 80-90 kDa isolate identified on the myeloblastic leukaemia KG1, the melanoma Hs294T and transfected COS cells and
(ii) a 160 kDa species on the primary colon carcinoma cell line HT29.

In addition, minor forms ranging from 52 to 200 kDa were also present on the
different T-cell types.
Further biochemical studies showed that CDw44 is N-glycosylated
and substituted with chondroitin sulphate.

When immunoprecipitates from

COS cells were treated with chondroitin ABC lyase, the molecular weight of
the 80-90 kDa species decreased

by 10 kDa.

When

the

HT29

immunoprecipitates were treated with chondroitin lyase, the minor 200 kDa
form was lost. DNA analysis showed complex patterns suggesting either a
multigene family or a molecule composed of multiple exons.

Furthermore, RNA analysis revealed three major bands of 1.6, 2.2 and
5.0 kb in a variety of haematopoietic cell lines.
When cancer cell lines were analysed three patterns were identified:
(i) one was identical to the 80-90 kDa species found by
immunoprecipitation (as outlined above),
(ii) a second showed transcripts of 2.0, 2.6 and 5.0 kb associated with
the 160 kDa protein and
(iii) a third was a composite of the other two patterns.

Nucleotide sequence data from a CD44 clone identified an open
reading frame (ORF) of 1354 residues which terminated in a short polyA tail,
19 bp downstream from a CATAA sequence.

The ATG encoding the first

Methionine was embedded in a consensus initiation sequence followed by
19 predominately hydrophobic residues which resemble a secretory signal
peptide sequence.

If this peptide were cleaved, it would produce 341

residues with an approximate molecular weight of 37.2 kDa, corresponding
to the CD44 core protein. The extracellular amino-terminal domain of the
protein encompasses 248 residues and is followed by 21 predominantly
hydrophobic

amino

acids

vMch

corresponds

to

the

predicted

transmembrane domain plus a 72 residue hydrophilic cytoplasmic domain.

The discrepancy between the predicted weight of the core protein
(37 kDa) and the proteins observed in immunoprecipitation experiments
(85-90 kDa) suggest that extensive 0-linked glycosylation occurs. The extra
cellular domain contains six probable N-linked glycosylation sites (Asn-XSer/Thr, X-Pro).

In proteoglycan core protein, a dipeptide SG forms the attachement
site for serine-linked chondroitin sulphate.

Analogous sites appear at

residues 160, 170, 211 and 238 in the extracellular domain of CD44.

Investigations on a baboon lymphoid cell line (Idzerda M

1989)

revealed a 37 kDa CD44 core polypeptide containing an additional 53 kDa
due to post translational modifications.

Such modifications include the

addition of chondroitin sulphate and extensive N- and 0-linked glycosylation
in the cytoplasmic domain.

When mouse Pgp-1, the murine equivalent of CD44 is compared with
human Hermes antigen (CD44), a high degree of sequence conservation is

7

observed.

Both the transmembrane and cytoplasmic domains are highly

conserved with 96% homology between the two. In both murine and human
sequences, the N-terminal globular domains are homologous to cartilage
proteoglycan core and link protein. Such levels of homology suggests that
these regions may be functionally important.

The proximal extracellular region on the other hand has undergone
immense divergence, displaying only 42% homology between murine and
human species, which may have consequences for the function of the
protein.

Wolffe et ai-, (1990) found 47% homology between the mouse and
human extracellular domain. It is in this region of the human protein that the
epitope for the mAb Hermes-3 is reported to reside. Hermes-3 blocks the
binding of lymphocytes to mucosal HEV. The alternative sequence in the
mouse may contain an equivalent epitope for the mAb.

Again, these

sequence differences may reflect functional differences.

Further evidence for glycosylation comes from studies on cDNA
encoding mouse Pgp-1 (Wolffe^a}., 1990). The polypeptide precursor was
synthesised in the presence of an inhibitor of N-linked glycosylation called
Tunicamycin, producing a protein of 50 kDa.

After 30 minutes, this was

‘chased’ into a 65 kDa form due to the addition of 0-linked sugars.
Synthesis in the absence of the inhibitor lead to the production of a 65 kDa
form which was chased again after 30 minutes into the mature 85 kDa form

8

seen on sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDSPAGE). The difference between the 50 kDa precursor (in the presence of
inhibitor) and the 65 kDa precursor (in the absence of inhibitor) was
attributed to co-translational addition of a predicted five asparigine-linked
high mannose oligosaccharides.
The most prevalent 85 kDa form is due to the processing of the
asparagine-linked oligosaccharides to complex type structures and the
addition of 0-linked oligosaccharides. The difference between the predicted
38 kDa species and the observed 50 kDa precursor found in the treated cells
implies there may be further modifications to the protein core.

Following
Haematopoietic

the

characterisation

or Standard

of

CD44-termed

the

85-95

CD44H

kDa

form

or CD44S,

as
fresh

evidence emerged suggesting a second form of the protein which appeared
to be present initially on epithelial cells. In addition, the expression of the
epithelial form is generally upregulated by neoplastic transformation.
(Stamenkovic ^aJ., 1991).

This form of CD44 - termed CD44E - is a distinct polypeptide which contains
an additional extracellular domain interposed proximal to the membranespanning domain of CD44.

The coding sequence is enlarged by 400 bp.

The immunoprecipitated protein has an approximate molecular weight of
130 kDa and is distinct from the larger 180-200 kDa isoform that arises due
to the addition of chondroitin sulphate.

Dougherty ^

(1991) isolated a similar protein from the cell line

KglA designated CD44R1. This immunoprecipitate contains the additional
132 amino acid insert and sites for N-linked glycosylation found in CD44E
(Stamenkovic

1991).

In addition, the region also contains an arginine

dipeptide sequence, which may serve as a site for postranslational cleavage
by proteases, producing a soluble form of CD44 such as that found in the
serum (Ristamaki et

1994).

Studies on human foreskin keratinocytes

(HFK)

revealed

the

existence of an alternate core protein for CD44E (Brown et ^., 1991). This
core protein contained an additional 14 kDa in the extracellular domain of
the 37 kDa core protein of CD44.

This region was designated ECAR.

Sequences flanking this region are identical to that of the 37 kDa core
protein implying CD44E isoform probably originates due to alternative
splicing of a common gene.

The extra 32 amino acids in CD44E core

protein are spliced in the region near the carboxyl terminal of the
extracelluar domain. This core protein also undergoes glycosylation and
modification to ultimately yield the CD44E isoform.
All this evidence implied large diversity within the molecule. Up to this
point, three broad divisions had been categorised:
(i) the 80-90 kDa haemopoeitic form,
(ii) the 110-160 kDa isoform which incorporates the epithelial
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CD44R1 isoform and
(iii) the large 200 kDa isoform which arises due to chondroitin
sulphate addition.

Additional insertions were identified in the extracellular domain (Jackson M
aj., 1992) which distinguished six different CD44 variants that are generated
by alternative splicing of five different exons in a discrete site in the
membrane proximal region. The multiple transcripts originate by the tandem
insertion of individual sequence inserts. In this study, five individual inserts
were defined and designated B-F (see Fig.1.2)
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Fig 1.2. CD44 Variant Isoforms

CD44 VARIANTS
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CD44A = Haematopoietic form of CD44
CD44B-F = CD44 variants generated by insertion of 5
sequence casettes into a single site within
the extracellular domain.
(Jackson elaL., 1992)
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CD44B is the equivalent of CD44E or CD44R1.

CD44C is identical to

CD44D except for the absence of the first thirty three amino acids from the
amino terminus. CD44D is identical to CD44E except for a GC inversion,
converting an Arginine to Alanine.

CD44E and CD44F are the most

complex, each containing four inserts arranged in tandem.

Each of the five exons contained a high proportion of serine and threonine
residues, potential sites for 0-linked glycosylation. However, only one exon
contained the corresponding sequence motif for N-linked glycosylation. The
Ser-Gly-X-Gly motif which characterises a potential site for chondroitin
sulphate addition was found on exon 4 (Brown et aj., 1991). Further analysis
(Screaton et al.,1992) identified nineteen exons over 50 kb of DMA in a
human YAC clone, twelve of which can undergo alternative splicing,
facilitating significant diversity within the gene.
In the membrane proximal extracellular domain, ten exons between exon 5
and exon 15 can undergo alternative splicing. Within these exons, there are
alternative splice donor sites (exon 5) and alternative splice acceptor sites
(exon 7) (see Fig 1.3).
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Figure 1.3 Genomic Structure of CD44H
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9*9

exons 6-14 or variants 2-10 can be alternatively
spliced into the CD44 mRNA to form higher
molecular weight variant isoforms. The variant
exon vl is found only in the rodent CD44
genome (Patel Mai •, 1995).

All isoforms differ from CD44H by the insertion of sequences coding
for additional amino acids. They share a single transmembrane region and
150 N-terminal amino acids.

Tolg ^

(1993)

suggested

similar

conclusions based on murine cDNA clones. The latter identified the variant
region consisting of 10 exons ranging in size from 90-207 bp. The exons

14

were separated by non-coding introns ranging in size between 0.3-4.2 kb. In
all, variant CD44 stretches for approximately
nomenclature was suggested which would
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kb.

incorporate

A common
the

different

designations based on the additional exons present in the standard CD44
isoform (see Table 1.1.). CD44 which carries no additional exons is termed
Standard CD44 or CD44S.

Variant isoforms carrying splice inserts are

distinguished by the exons it contains i.e. v1-v10 or exon 6 - exon 14.

ble 1.1

Variant isoform

Exon(s) present

v2

6

v3

7

v4

8

v5

9

v6

10

v7

11

v8

12

v9

13

vIO

14

15

The variant CD44 isoforms may contain 1 or more exon inserted into the
extracellular domain, i.e. CD44E contains the exons 7 - 14 or the variants
3 -10.

1.3. Distribution of CD44
CD44 is a widely distributed class of cell surface glycoprotein (see
Table 1.2).

CD44 expression has been characterised on lymphocytes,

macrophages, fibroblasts, epithelial cells and keratinocytes (Flanagan ^ ^.,
1989) It is expressed in a wide range of epithelia including skin, cheek,
tongue, oesphagus, vagina, intestines, oviduct and bladder (Alho and
Underhill, 1989). In the brain, CD44 is found exclusively in the white matter.
Continually CD44 negative tissues include liver hepatocytes, kidney tubular
epithelium, cardiac muscle and the testis (Lesley MiJ-, 1993).
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Table 1.2 Detailed distribution of CD44 in normal human tissues:
Staining with Anti-CD44 antibody

Organ/Tissue type
Haemopoietic system
Thymus cortex
Thymus Medulla
T and B lymphocytes
Erythrocytes

++
++
+/-

Nervous system
CNS grey matter
CNS white matter
Peripheral nerves

++
++

Epidermis

++/-

Gastrointestinal epithelium
Tongue, oesphagus
Stomach, small and large intestine

++/+/-

Liver
+

Hepatocytes
Biliary epithelim
Urogenital System
All kidney tubules and glomeruli
Epithelium of ureter and bladder, prostate and urethra
Detrusor muscle ofbladder

++
4*+

Respiratory system
Trachea, pseudostratified epithelum
Bronchioles
Alveolar epthelum
Mixed glandular tissue of the trachea

++
+

Pancreas
Acinar epithelium
Ductal epithelium
Islets of Langerhans

-

Muscle
++

Smooth
Skeletal
Endocrine Tissue
Thyroid Follicular cells
Parathyroid
Pituitary
Adrenal cortex
Adrenal medulla

++/-

Miscellaneous Tissue
Connective tissue
Cultured fibroblasts
Vascular endothelium

++
++
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1.4. Functions of CD44
1.4.1. CD44 and T-cell activation:

T lymphocytes are induced by ligation of the CD3/TCR complex by
MHC and antigen which initiates a cascade of biochemical events that are
essential for activation. In addition, a number of co-stimulatory signals are
required.

Cell surface markers provide the necessary stimuli for T-cell

activation in combination with CD3/TCR signals.
include the receptor/ligand

Examples of such stimuli

pairs CD2/LFA-3, LFA-1/CAM and CD44

monoclonal antibodies.
Initial events in CD44 mediated activation involve the exposure of an
activation epitope of CD2. In a T-cell/keratinocyte model, co-engagement of
CD2 and CD44 lead to a rapid augmentation in T-cell adhesivness plus an
increase in intracellular calcium concentration (Conrad eta]., 1992).
The monoclonal antibody NIH44-1 brings about increased T-cell
proliferation in response to a mitogenic CD3 mAb or a pair of mitogenic CD2
mAb (Denning et

1990) This upregulation is most dramatic in the CD2

mediated system (Shimizu ^ af., 1989).

In an in vitro activation assay of

peripheral blood mononuclear cells (PBMC) (Denning et

1990), CD44

mAbs increase CD2 mediated T-cell triggering in a number of ways:
(i) by inducing IL-2 release from monocytes,
(ii) by adhering to monocytes and increasing T-cell/monocyte
adherance and
(iii) by binding to T-cells and augmenting the release of IL-2.

18

Only peripheral blood T-cells are receptive to CD44-meditated activation.
Murine CD44 plays a role as a co-stimulatory molecule for the
activation of CD4^ cells as well as cultured

cells (Sommer et^., 1995).

Anti-CD44, in conjunction with anti-CD28, triggers IL-2 production in freshly
isolated splenic CD4^ T-cells.
Triggering of the CD44 antigen also exerts an effect on T-cell
adhesion.

CD44 involvement is mediated by CD44S on erythrocytes

(Conrad ^ a}., 1992).

The mAb H4C4 (anti-CD44) induces homotypic

aggregation in a variety of leukocyte cell lines (Belitos et af., 1990).
Studies on keratinocyte/T-cell binding found that preincubation of cells with
a mAb to CD44 increased adhesivness by a factor of six. However, certain
elements were required:
(i) an intact cytoskeleton
(ii) metabolic energy
(iii) magnesium ions.
(iv) adhesion was inhibited by anti-Leukocyte function asssociated
antigen-1 (LFA-1) and anti-Intracellular Cell Adhesion Molecule (ICAM)
(Bruznzeel

1993). Adhesion is mediated by the LFA-1 pathway but not

LFA-3, the ligand for CD2. ICAM was found to be involved as mAbs against
ICAM inhibited adhesion.

1.4.2. CD44 and Hyaluronate
Hyaluronate (HA) is thought to play an important role in a number of
biological

phenomena

including

cell-cell
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adhesion,

cell

migration.

embryonic development and pathogenesis by providing a highly hydrated
matrix through which cells can migrate. CD44 has been found to be a cell
surface receptor for HA (Aruffo ^ a}., 1990, Culty et a}., 1990).

The

extracellular domain of CD44 is homologous to the region of cartilage link
protein that binds HA (Goldstein et^-. 1989 , Stamenkovic ^aj., 1989). The
interaction between HA and CD44 is important for cell movement and
adhesion (Underhill, 1989). CD44 recognises a six sugar sequence of HA
(hexasacharide) consisting of three repetitions of a basic disaccharide
repeat motif which consists of glucuronic acid and N-acetylglucosamine
joined (31-3. The repeat elements are (31-4 between N-acetlyglucosamine
and glucuronic acid to form a polymer.
Certain lymphocyte cell lines which express CD44 can bind HA
coated dishes and this binding can be blocked by mAb to CD44 (Lesley ^
a]., 1990).

Similarly, the binding between a B-lineage hybridoma and a

bone marrow derived stromal cell line can be attributed to CD44/HA
interactions, suggesting a possible mechanisim for cell-cell recognition
(Miyake et al., 1990b). In addition, the interaction of CD44 with HA has been
shown to

mediate

the

divalent

cation

independent

aggregation

of

macrophages and fibroblasts (Culty et li-. 1990).
Binding of the receptor to HA is thought to occur in a co-operative
manner (i.e. more than one receptor can interact with the same molecule of
HA) (Underhill, 1989). The repeating disaccharide unit provides a highly
multimeric ligand with high binding avidity.

In Jurkat CD44 transfectants,

reorganisation of the cytoskeletal proteins may be a prerequisite for HA
binding. Reorganisation of cytoskeletal proteins can be induced by multiple
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signalling pathways including calcium mobilisation and activation of protein
kinase C, resulting in the clustering of CD44 on the cell surface (Liu ^ aj.,
1996).
Not all isoforms of CD44 bind HA and in some cell types, activation of
cells or ligation of CD44 mAbs is required for HA binding.

The affinity of

CD44H for HA varies according to the cell type in which it is expressed.
Normal lymphocytes and certain CD44 positive lymphoid cell lines do not
bind HA or adhere to a HA coated substrate (Lesley and Hyman, 1992).
Also several CD44 positive non-lymphoid tumour cell lines fail to bind HA. In
murine systems, many normal CD44 negative haematopoietic cells fail to
bind to HA. However, treatment with a mAb IRAWB 14 can rapidly induce
binding to HA in these cells (Lesley and Hyman, 1992). Exposure to phorbal
esters and certain cytokines can induce adhesion to HA vja CD44 in murine
lymphoma cells and both human and murine lymphocytes.
Three activational states of CD44 binding to HA are thought to exist:
(i) a non-activatable resting state which cannot easily be induced to
bind to HA,
(ii) an activatable state whereby cells can be rapidly induced to bind
HA and
(iii) an active state which readily bind to HA.
Distinct epitopes in the extracellular domain of CD44 participate in
the binding to HA. The N-terminal and central regions may interact and
regulate HA binding to cell surface CD44 (Liao et^-, 1995). Two clusters of
basic amino acids in the NHg-terminal domain and specific amino acids
within these domains have been found to be important in HA interactions. A
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cluster of positively charged amino acids situated membrane proximal to the
cartilage link homologous domain play an important role in CD44-HA
interactions. Arginine and Lysine residues within this cluster and a cluster
within the NH2-terminal link protein homologous domain are strongly
associated with CD44-HA interactions. (Peach eta]., 1993).

The cytoplasmic domain is also involved in HA binding. Mutant CD44
molecules with a truncated cytoplasmic domain exhibit diminished affinity for
HA (Perschl et aj., 1995).

However, dimerization of CD44 molecules

restored the binding efficiency suggesting the cytoplasmic domain may play
a role in the clustering of CD44 at the cell surface to facilitate HA binding.
The cytoplasmic domain interacts with cytoskeletal proteins, especially with
ankyrin, a protein important in membrane cytoskeletal interactions, which
may have implications for CD44-HA binding.

In the cytoplasmic and

transmembrane domains, there are two cysteine residues which are
conserved in all mammalian CD44 molecules. The cysteine residue located
at position 286 in the transmembrane domain is critical for HA binding (Liu eX
^., 1996). Cells expressing mutated CD44 containing a serine to glycine
substitution at position 325 or a serine to alanine substitution at position 327
within the cytoplasmic domain are unable to bind HA (Pure et a]., 1995).

CD44/HA binding is also regulated by the degree of glycosylation.
0-linked glycosylation has been found to modulate CD44-HA interaction and
that a cluster of amino acids in the the area of CD44 equivalent to the B loop
of Link protein appear to be essential for HA interaction (Dasqupta M
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1996). 0-linked glycosylation of higher molecular weight isoforms appears
to have a lesser effect on CD44-HA binding. Treatment of various CD44 cell
lines with an inhibitor of N-linked glycosylation results in a loss of HA
binding. In contrast, a substance that inhibits conversion of high mannose
oligosaccharides to complex N-linked carbohydrate results in either no
change or an increase in CD44-mediated adhesion to HA. High mannose
N-linked glycans may help maintain the HA binding domain. Glycosylation
may promote different CD44 associated adhesive properties in different ceil
types and may have a regulatory function (Bartolazzi M aj., 1996).
Modification of the variant isoforms may also play a role in regulating
CD44/HA interactions.

CD44E is rich in serine and threonine residues

which may be used for glycosylation (Bennet et ai-, 1995).
Keratan sulphate also modulates CD44 adhesion by a mechanisim
which is as yet unclear.

Removal of

keratan sulphate greatly increases

CD44/HA adhesion (Takanashi ^af., 1996).

1.4.3. CD44 and the extracellular matrix

The broad tissue distribution of CD44 suggests it may promote
adhesive interactions by a wide variety of cells (St. John et a}., 1990).
However, the interaction of CD44 with other extracellular matrix (ECM)
proteins remains unclear. The ECM modulates cell adhesion, proliferation
and

differentiation.

Prominent

proteoglycans and collagen.

components

of

the

ECM

include

The affinity of CD44 for collagen is low.

However, a chondroitin sulphate modified CD44 purified from lymphocytes
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has been shown to bind collagen type I as well as fibronectin and laminin in
in vitro binding assays (Jalkanen and Jalkanen, 1992). The modification by
chondroitin sulphate is essential for binding, therefore only the 180-200 kDa
isoform of CD44 has this ability.
Recently, another ligand for CD44 was identified.

The production of a

sulphated proteoglycan by a mouse T-cell line induced homotypic cell
aggregation by specifically binding to CD44 (Toyama-Sorimachi
Myasak, 1994).

and

The proteoglycan, termed gp®°°, strongly resembles the

macromolecule Serglycin. The biological significance of this ligand is as yet
unclear.
Another ligand for CD44 is the cytoskeletal protein ankyrin, which links
plasma membrane to the underklying cytosklelton (Haynes e\ aj., 1991).
Ankyrin binds to the cytoplasmic domain of CD44 and provides a bridge to
the cytoskeleton (Kalomiris M iJ-, 1988).

Phosphorylation of CD44 by

protein kinase C and binding of GTP to CD44 enhance its interaction with
ankyrin.
CD44 also binds to the cytokine Osteopontin (Eta-1) which mediates
various cellular functions including cell attachement and chemotaxis (Weber
et aJ., 1996). CD44 and Eta-1 are often secreted by metastisizing tumour
cells, indicating the secretion of Eta-1 and the expression of CD44 may
provide a potential mechanisim for tumour cell dissemination (Weber ^ ^.,
1997).

As yet the physiological

implications

interactions are unclear.
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of these CD44-ligand

1.4.4. CD44 and lymphocyte homing.

Lymphocytes recirculate continously from the blood to the lymphoid
tissues as an essential component of the immune system. Their migration
across the blood vessels and subsequent extravasation into lymphoid
tissues in a process known as ‘lymphocyte homing’.

It is mediated by

interactions between homing ‘receptors’ on lymphocytes and their ligands
on specialised post capillary endothelial cells lining HEV’s in lymph node,
mucosal associated lymphoid organs (Peyer’s Patches, appendix and sites
of inflammation).
Initial studies described a 90 kDa lymphocyte surface glycoprotein,
recognised by the the mAb Hermes-1 which appeared to be involved in
endothelial cell recognition and lymphocyte trafficking in man (Jalkanen M
al., 1986).

This glycoprotein was selectively expressed on normal or

transformed lymphoid cells, that are able to recognise and bind to HEV. The
glycoprotein carries the predominant cell surface epitope recognised by
heterologous anti-human lymphocyte antibodies which can interfere with
binding of lymphocytes to HEV.

It also was similar (but not identical) in

structure to the mouse antigen Mel-14, which was considered to be the
murine counterpart of CD44.

Also, in Fluorescence Activated Cell Sorting

(FACS) analysis of a cloned cell line, this glycoprotein was found to co
select with Hermes-1 antigen which is identical to CD44.
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Further analysis

revealed mAbs that selectively inhibit lymphocyte binding to lymph node or
mucosal HEV and that these mAbs recognise CD44 (Jalkanen

1987).

There is no evidence to suggest that HA is involved in the homing
process. The mAb Hermes-3 blocks adhesion of lymphocytes to HEV frozen
sections but does not block HA dependant adhesion in a B-cell line
transfected with CD44 to cultured rat endothelium (Stamenkovic M
1991). Also the membrane proximal portion of the external domain of CD44
is recognised by the mAb Hermes-3 whereas the HA binding region appears
to be in the N-terminal membrane-distal portion of the molecule (Goldstein et
ai., 1989).

However,

the adhesiveness

of lymphocytes to cultured

endothelial cells and to stromal cell lines is mediated by HA-binding (Aruffo
e\ aj., 1990; Stamenkovic et aj., 1991; Miyake et a}., 1990a) implying
CD44/HA

interactions

may

be

involved

in

lymphocyte/endothelial

interactions under certain circumstances.
In contrast to these findings, peripheral lymph node lymphocytes,
stripped of cell surface CD44 enter lymphoid organs normally (Camp et aJ-.
1993) but did however, result in inhibition of oedema and leukocyte
infiltration at a site of cutaneous delayed type-1 hypersensitivity twenty-four
hours after challenge, suggesting a role for CD44 in homing in areas of
inflammation but not for normal lymphocyte recirculation.
Many of the findings on the role of CD44 in lymphocyte homing have
been based on the Stamper and Woodruff (1976) in vitro
assay.

frozen section

This assay appears to be concerned with the first phase of

lymphocyte/HEV interaction. A subsequent adhesion assay (Ager, 1987) is
based on the latter stages of HEV/lymphocyte interaction and is performed
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under still conditions using living HEV. Use of the Ager, 1987 assay and
porcine CD44 demonstrated that porcine CD44 did not block the binding
sites on HEV for lymphocytes. The epitopes of CD44 which are recognised
by several mAb and by a polyclonal antibody do not appear to be involved in
binding.

Similarly, the N-terminal part of the CD44 molecule was not

involved in binding. In addition, lymphocytes retained their full ability to bind
to HEV after the CD44 molecules had been cross-linked by antibodies or
had been stripped from the cell surface, again implying CD44 expression is
not necessary for the latter stages of binding to HEV.
Therefore, CD44 may play a role in the early stages of lymphocyte
HEV interactions or it is also possible that CD44 indirectly plays a role in the
latter stages by delivery of a signal to other adhesion molecules once bound
to its own ligand.

The tissue distribution of CD44, the failure to identify

specific epitopes or molecular forms whose expression is related to the
organ specificity of lymphoid cell lines and the lack of supportive evidence
from in vivo experiments appears to be contrary to the role of CD44 as a
specific homing receptor.

1.4.5. CD44 and inflammation.
Expression of CD44 is upregulated in synovial tissue and fluid from
patients with osteoarthritis and those with tissue trauma. HA is an important
component in rheumatoid arthritis (RA) and a decrease in HA is thought to
be an important factor in joint degeneration. Decreased levels of HA in RA
may be due to increased binding by CD44.
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The level of inflammation is

related to the degree of CD44 expression and is upregulated on many cell
types in patients with RA (Haynes

1991).

In contrast, in another study by Henderson e\ a]., 1994, the level of
CD44 in rheumatoid synovium was found to be decreased with rheumatoid
cells displying altered morphology The reason for this discrepancy is not
clear. CD44 variants have also been implicated in inflammatory synovitis
with CD44 the most prevalent form expressed, followed by CD44E. CD44 v6
is also implicated in the inflammatory process, expressed on synovial cells
and synovial interstitial cells (Hale M a]-. 1995). At this point, the role of
CD44 in inflammation is unclear but warrants further study.

1.4.6. CD44 and the metastatic process.

Several lines of evidence suggest a role for CD44 in the metastatic process.
The mechanism of dissemination bears a strong resemblance to that of
lypmhocyte trafficking. Both involve mobile cells, cellular interactions with
and migration yja the ECM and endothelium and cellular transport vja
lymphatics and blood (Griffioen et^., 1994).
CD44 expression is high in proliferating cells in contrast to their non
proliferating counterparts i.e in the dividing epithelia at the base of the crypts
of Lieberkuhn in the small intestine and in the dividing epithelia of the colon
but is absent in the non-dividing cells (Alho and Underhill, 1989). CD44 is
expressed

in tumourigenic

variants

of the

murine

thymoma

SL12.

Invasiveness of human bladder cancer corrielates with CD44 expression
(Underhill, 1989). Malignant cells have been found to express higher levels
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of CD44 compared with non-malignant cells (Stamenkovic
addition, an isoform of CD44 containing

1989).

In

an additional 162 amino acids,

inserted into rat CD44 has been shown to confer metastatic behaviour to a
non-metastasising tumour cell line (Gunthert et aj., 1991).

Expression of

CD44 in tumour cells may help to regulate tumour growth, invasiveness and
enhance metastatic potential.
Most tumour cells express the standard form of CD44 - CD44H.
Expression of CD44H in a human B-cell lymphoma promotes tumour growth
and metastasis. Most tumour cells express variant isoforms of CD44, in
addition to CD44H. The pattern of expression however, is variable but most
tumours express a combination of CD44H with the variant isoforms.
CD44v6 has been particulary implicated in the metastatic process.
Upon antigenic stimulation of rat lymphocytes in vivo, the frequency of the v6
isoform is increased (Arch et af., 1992). In humans, leukocytes express low
levels of splice variants, but T lymphocytes can be upregulated to express
these variant isoforms, again with v6 predominating (Koopman et aj., 1993).
CD44v6

promotes

metastatic

behaviour

in

non-metastatic

cell-lines

(Gunthert ^ a}., 1991) and promotes metastatic spread from a subcutaneous
injection site in isogenic animals (Herriich et^., 1993). High expression of
VD44v6 and CD44H are associated with aggressive behaviour and poor
prognosis in non-Hodgkin’s Lymphoma (Jalkanen et aj., 1990, Sy M
1990).
The variant isoforms of CD44 have been found to be upregulated in
various human cancers such as colon, gastric, breast carcinoma and certain
tumours

of

the

nervous

system
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(see

Table

1.3.).

Table 1.3. Expression of CD44 isoforms in human cancer.
Positive or negative
correlation with
tumour progresion/
clinical outcome.
survival (-)
(3, v5, v6)

Tumour

Surface expression
of CD44 isoform

Rt-PCR evidence
for CD44 variants

Breast

v3,v5,v6,v7/8,v10 (-i-)

ND

v3,v5,v6,v7/8,v10
(+)

v3-v10, v4-v7, v8vIO,complex pattern.

progression (+)
(v3-v10)

v3,v4/5,v6,v8/9 {+)

ND

ND

ND

ND

v5, v6(-i-)

v3-v10,
complex
pattern
v3-v10, v5, v6

v9(-h)

ND

survival (-)

v6(-h)

v6-v10

progression (+)

v3,v4/5,v6 (-I-)

ND

ND

ND

v3-v10,
pattern.
v3-v10,
pattern
ND

Gastric

Colon

ND
non-Hodgkin’s
Lvmohoma
Skin (Souamous celh
Cervix

v6 (+)

Glioblastoma
Neuroblastoma

ND

complex

ND

complex

progression (-t-)
progression(-f-)
ND

no epitopes

v6 (-)
v3-v10,
v8-v10,v4v7,complex pattern
no variants

CD44S {+)

ND

survival (-i-)

v6 (-)
v7/8 {+)

ND

(+)/(-) indicates increased/decreased CD44 epitope expression compared with normal tissue.
ND, not determined.
(Sleeman et al-, 1995)

30

1.4.7.

CD44 and non-Hodgkin’s lymphoma.
Adhesion molecules that direct the homing of lymphocytes in normal

states also regulate the dissemination of their malignant counterparts, the
non-Hodgkin’s lymphomas (NHL).

NHL are the malignant equivalents of

normal lymphoid cells which are arrested at certain stages of maturation and
share many characteristics with normal lymphoid development (Horst M aj.,
1990).

CD44 expression in NHL appears to parallel that displayed by

normal T-cell and B- cell ontogeny, it is strong in the earliest phases of
development, reduced in the following stages of differentiation and is
increased again in the later more mature stages (Stauder^^., 1995).
Ample evidence exists that CD44 is involved in the dissemination of
NHL (Gunthert

1995). The ability of malignant lymphocytes to bind to

HEVs in vivo was responsible for the dissemination of murine lymphomas
(Bargatze Ma}., 1987). Significant correlation was found (P<0.001) between
the expression of CD44 and clinical stage in a diffuse large-cell lymphoma of
the B-lineage.

Lymphomas exhibiting low or negative CD44 expression

displayed a more limited spread (Pals ^ aj., 1989).

However, lymphoma

dissemination was observed in some cases without CD44 expression,
indicating CD44 may play a role in tumour spread but that it may not be
essential. In a study of 104 NHL, CD44 negative lymphomas had a more
favourable outcome and spread less often compared with CD44 positive
lymphomas (Jalkanen ^af., 1990).
Although earlier studies suggested a dominant role for CD44 in
homing, it has since emerged that a major function of CD44 is binding to HA.
The capacity of tumour cells to bind to HA via CD44 most probably plays a
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role in dissemination.

HA production is increased at sites of tumour

production and this may have an effect on cell motility since CD44 positive
melanoma cells in vitro display firmer attachment to and greater cell mobility
to HA-coated substrate. HA may provide a molecular bridge to facilitate the
binding of tumour cells to components of the ECM (Sy et af., 1992).
Initial accounts of CD44 involvement in NHL dissemination focused
on the standard form of CD44 - CD44H (molecular weight = 85-95 kDa).
However the variant isoforms also have a role to play in metastatic spread
(Pals

1997). The latter could be frozen or even blocked by co-injection

of variant specific antibodies with the metastasising cells. Over-expression
of this metastatic variant in a non-metastasising cell line led to lymphogenic
metastatic spread.

There is significant correlation between unfavourable

prognosis in a high grade malignant lymphoma and a strong upregulation of
CD44v3 and CD44v6 iosforms (Terpe ^ aj., 1994).

Strong expression of

CD44v6, in conjunction with overexpression of CD44H is highly correlated
with unfavourabe clinical course in patients with NHL (Stauder et id-, 1995).

1.4.8. CD44 as a marker of prognosis in NHL

Serum

CD44

levels seem to correlate well with the clinical

progression of NHL and may serve as a useful prognostic marker of disease
progression (Guo ^ aj., 1994).

In this case, a slightly smaller isoform of

CD44 (sCD44) can be identified with a molecular weight of 70-80 kDa.
sCD44, which is lacking a cytoplasmic domain, is able to bind to HA in vitro
suggesting that HA-binding is involved in dissemination.

sCD44H and

sCD44v6 can be detected in the sera of healthy individuals but levels are
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elevated in patients with untreated lymphoma and the levels became lower
in serial estimations from patients who achieved a complete response
(Ristamaki et aj., 1994). The origin of sCD44 in sera is unclear at present
(Sy Mil-, 1997), but lymphoma cells, tissue lymphocytes and PBL in cell
culture can shed CD44 (Ristamaki ^ aj., 1997).

In healthy individuals

sCD44 may originate from normal lymphocytes. Similarly, sCD44 from
lymphoma patients may originate from lymphoma cells.
As sCD44 levels in serum seem to correlate well with prognosis of
NHL, sCD44 measurement in serum would provide a rapid, inexpensive and
relatively non-invasive prognostic marker for NHL.
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1.5. Enzyme Linked Immunosorbent Assays

1.5.1. Introduction
Immunoassays are widely used in both research and the clinical
laboratory. Immunoassays are quick, easy to perform, reliable, inexpensive,
highly specific with low detection limits within the nanogram to picogram
range. Because of their high selectivity, complex analytes such as serum or
urine can be assayed (Hage M

1993).

Immunoassays use antibodies

and antibody fragments to detect specific components in a sample.

1.5.2. Classification of Immunoassays
Gosling (1990) characterised immunoassays into six categories:
(i) Competitive assays of antigens or haptens with labelled analyte:
This assay system uses a limited amount of antibody and the analyte is
labelled with a radioactive, flourescent, luminescent or enzyme label.
(ii) Competitive (reagent limited) assay for antigens and haptens with
labelled antibody. An immobilized analyte is present in a constant , limited
amount in the assay vessel.

This assay is suitable for highly purified

monoclonal or affinity-purified polyclonal antibodies.
(iii) Endpoint Immunoassays the involve direct detection of immune
complexes:
Assays

included

in

this

group

include

precipitation,

nephlometric,

turbidometric, particle agglutination and particle- counting assays.
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(iv) Immunoassays which involve labels in which the principal
reagents are used in excess;
Such

assays

include

immunochemiluminometric

assays,

immunoradiometric assays (IRMA), immunoflourometric assays (IFMA) and
most enzyme- linked Immunosorbent assays (ELISA).
(v) Immunoassays for quantifying specific antibodies:
Excess antibody is immobilized on a solid phase, test serum is added,
the amount of specific antibody which is captured by the antigen may then
be quantified by specific labelled antibodies that bind to the constant region
of the immunoglobulin class of interest.
(vi) Immunoassays involving labelled reagents in which an antigenantibody reaction results in the modulation of the signal:
These simple and fast assays are often called ‘separation free’ or
‘homogenous’ assays. These assays are commonly used for drug-testing in
urine and blood where low detection limits are not essential.

Enzyme immunoassays (EIA) employ enzyme labels to monitor an
antigen-antibody reaction. EIA can be broadly classifed into two groups:
(i) Heterogenous EIA:
In heterogenous EIA, the activity of the enzyme is not affected by the
antigen- antibody reaction.
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(ii) Homogenous EiA:
In homogenous EIA, the antigen-antibody interaction modulates the
activity of the enzyme, eliminating the separation step.

The ELISA technique is a simple, sensitive, rapid and versatile
heterogenous enzyme assay used for the quantitation of antigens and
antibodies.
ELISA may be classified into two groups:
(i) Competitive ELISA:
Using either:
a) antigen-enzyme conjugates:
whereby antibody is immobilised onto the solid-phase. The
final product concentrations are inversely proportional to the concentration of
standard antibody/antigen added. These ELISAs are used to detect many
antigens such as Carcinoembryonic antigen (CEA) and human chorionic
gonadotrophin (hCG).

b) antibody-enzyme conjugates:
whereby antigen is coated onto the solid phase.

The conc

entration of product is inversely proportional to the concentration of standard
analyte in the assay.
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ii) Non-Competitive ELISA:
In non-competitve ELISA, analyte (usually antigen) is incubated with
an excess of antibody and final measurement is made via a second labelled
antibody.
Non-competitive ELISA may be sub-divided into:
a) A single-site non-competitive assay:
Either the antigen or the antibody is enzyme labelled. The substrate
concentration is inversely proportional to the concentration of test
analyte.

b) A two-site non-competitive ELISA:
Often termed a ‘sandwich assay’. Antibody is immobilised onto a solid
phase (e.g. microtitre plate surface). Test antigen is then added and
allowed to react with an excess of enzyme-labelled antibody directed
at the antigen. Detection is vja the addition of the enzymes corres
ponding substrate. Washing steps are required at each stage of the
assay to remove excess unbound material. The concentration of sub
strate is proportional to the concentration of standard antigen in the
reaction (see Fig. 1.4.).

(Note: The choice of ELISA for a particular application depends on the purity
and specificity of antibodies or antigens available)

37

Figure 1.4. Non-Competitive Enzyme Linked Immunosorbent Assay
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1.5.3. Components of ELISA
1.5.3.1

Antibodies in ELISA

1.5.3.1.1. Monoclonal Antibodies (mAb)
With the introduction of monoclonal antibodies (mAb), immunoassays
have been simplified and their specificity increased. Monoclonal antibodies
may be defined as a uniform homogenous antibody, directed at a single
epitope or antigenic determinant and produced continously from one cell
clone (Nakamura, 1992). Monoclonal antibodies offer improved continuity
of supply, better specificity (as they are isolated from a single clone) and
their specificity and affinity are well defined (e.g. interacting with a single
antigen or epitope).

However, there are certain limitations:

(i) They have a fixed affinity for their ligand which if low, makes it
unsuitable for use in a sensitive assay.
(ii) limited biological activity
(iii) lack of aggluntinating properties and
(iv) though monospecific, monoclonal antibodies may react with a set
of epitopes on closely related epitopes, making an assay non-specific.

Monoclonals can be generated from mice and murine cell lines, rats
and rat cell lines (Gosling and Basso, 1994). The production of monoclonal
antibody proceeds through five well recognised steps:
(i) Immunisation of selected animal,
(ii) Fusion with a hybridoma cell line,
(iii) Screening and Selection of hybridomas for antibody production.
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(iv) Cloning of cells containing antibody and
(v) Production of the monoclonal antibody using in vitro or in vivo
methods.
(Note: for a comprehensive review of these methods see: Principals and
Practice of Immunoassay, Eds. C.P. Price and D.J. Newman)

1.5.3.1.2. Polyclonal Antibodies
Polyclonal antibodies may be obtained by immunisation accross or
within an animal species.

Rabbits, sheep and goat are generally used to

make polyclonal antibodies but other species may also be used (i.e. bovine,
guinea pig and porcine sources). Compared to mAb, polyclonal antibodies
are easier to produce. A disadvantage of polyclonal antisera however, is the
lack of continuity between and within batches.

Furthermore, polyclonal

antisera may differ in antibody class, affinity, specificity or reactivity, even if
raised in the same animal.

1.5.3.1.3. Antibody Fragments
In certain assays, the presence of the

region of the antibody can

hinder the assay. The F^ portion of intact immunoglobulins contains binding
sites for complement, staphylococcal protein A and rheumatoid factor
amongst others, which interfere with the assay (Gosling 1990). Cleavage of
the F^ portion at the hinge region of the antibody molecule releases the Fab’
fragment of the molecule.

Use of this portion of the antibody provides a

direct means of overcoming F^ region interference.
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1.5.3.2.

Labels in ELISA

The first detection labels used in immunoassays were radioactive in
nature. However, the now well recognised dangers involved in the use of
radioactivity and the safe disposal of radioactive waste has lead to the
development of a wide range of alternative labelling systems. Commonly
used labels include luminescent, fluorescent, particle and enzyme labels
(Howanitz J.H. 1992).
In ELISA, enzymes themselves represent the label of choice. They
are safer and more stable compared with isotopic labels and they have a
high specific activity with low detection

limits.

A summary of the

requirements, allowing enzymes to function as appropriate assay markers/
labels is given in Table 1.4 (below).

Table 1.4 Requirements of Enzymes as Labels
• High specific activity as free and conjugated enzyme
• Availability of soluble pure enzyme at low cost
• High stability in free and conjugated form under assay and storage conditions
• Presence of reactive groups for covalent linkages
• Simple and gentle labelling methods
• Inexpensive and non-toxic substrates.
(Adapted from Porstman and Kiessig, 1992)

Many enzymes are available for use as labels.

Horseradish

peroxidase (HRP) and calf intestine alkaline phosphatase (CIAP) are
amongst the most commonly used. Horseradish peroxidase has a molecular
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weight of 44 kDa with suitable amino groups and carbohydrate residues
available for conjugation. Common substrates for peroxidase include 2,2’Azinobis(3-ethylbenzthiazolinesulfonic
(OPD)

and

TetraMethylBenzidine

Acid)
(TMB),

(ABTS),

o-PhenyIdiamine

permitting

detection

by

colourimetric, flourometric and luminometric methods. Calf intestine alkaline
phosphatase has a molecular weight of approximately 140 kDa. It contains
free amino groups which may be used to conjugate the label to an antibody.
The substrate of choice for CIAP is para - Nitrophenyl phosphate (p-NPP). A
summary of the more common chromogenic substrates, their corresponding
enzymes (as labels) together with some of their characteristics is given in
Table 1.5.

Table 1.5. Commonly used enzyme labels
Enzyme

Source

Alkaline

Calf

Phophatase

intestine

p-galactosidase E.coli

Peroxidase

Horseradish

pH

Specific

Substrates

Mol. Wt.

Optimum

Activity U/mg

9-10

1000

p-NPP

100,000

6-8

600

oNPG

600

5-7

4500

ABTS

40,000

TMB
OPD

Urease

Jack beans

10000

6.5-7.5
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Urea

483,000

1.5.3.3. Amplification Systems used in ELISA
The use of an enzyme label that incorporates final signal amplification
has the potential to further increase sensitivity in ELISA.

A number of

amplification systems have been developed and are available for this
purpose (Avrameas 1992).
An example of a common amplification system is based on the avidin
(streptavidin)-biotin interaction.

In this design, the glycoprotein avidin has

four binding sites for biotin (and hence a high avidity for biotin) , a secondary
biotin-labelled antibody in conjunction with avidin provides significant
amplification. Soluble avidin-biotinylated enzymes are available for use in
the Avidin-Biotin Complex (ABC) technique (Hsu Mai-. 1981, Wilcheck and
Bayer, 1990).

Streptavidin, isolated from Streptomyces avidinii. has a

similar affinity for biotin and may replace avidin to overcome high non
specific background in an assay system.
Another common amplification strategy uses an enzyme cascade
system to increase the signal (Kricha, 1992). This procedure can amplify the
signal 100-fold.
Alkaline phosphatase converts the substrate nicotinamide adenine
dinucleotide phosphate (NADP^) into nicotinamide adenine dinucleotide
(NAD^).

This activates an alcohol dehydrogenase cycle which yields

formazan dye molecules which are proportional to the amount of NAD^
generated by alkaline phosphatase (see Fig. 1.5).
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Fig. 1.5. Enzyme Cascade System for the
Amplification of Alkaline Phosphatase
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Other amplification

systems include the use of fluorometric

or

luminescent amplifiers and an alternative enzyme cascade system ( Mize ^
al., 1989)).

I.5.3.4. The Solid Phase in ELISA
The characteristics of a good solid support are high antibody loading
and low non-specific binding. Proteins attach to the solid phase surface by
different mechanisms such as passive adsorption , covalent immobilisation
and

via

linking

immunoglobulins.

agents

such

as

Protein

A,

streptavidin-biotin

or

Antibody can be attached to various materials such as

nylon, silicone or polystyrene.
choice for most ELISA.

Polystyrene plates are the solid phase of

Polystyrene plates have been developed to allow
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optimal antibody binding and the well size and shape are designed for
maximum antibody coating and temperature conveyance.
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1.6. Molecular cloning
Molecular cloning permits the isolation of discrete sections of a
genome and their subsequent characterisation. The basic principles in gene
cloning can be outlined as follows:
(i) A fragment of DNA, containing the gene of interest, is
inserted into a circular DNA molecule called a vector to
produce a recombinant DNA molecule (chimera). Examples
of vectors include plasmids, bacteriophage and cosmid vectors.
The choice of vector depends on a particular application.
(ii) The vector is transformed into a host cell such as bacteria or
yeast where it can replicate to produce numerous copies of
itself and one or more copies of the gene that it carries.
(iii) The recombinant DNA fragment can be analysed by any or
all of several methods:
• Agarose gel electrophoresis
• Nucleic acid blotting - demonstrates the homology of
selected nucleic acid sequences:
• Southern blotting - allows the detection of
fragments complimentary to a given sequence of
RNA or DNA
• Northern blotting - permits the detection of RNA
• Western blotting - following electrophoresis of
the isolated protein, the protein bands are
transferred from a poly-acrylamide gel onto a
nitrocellulose membrane to which they bind
strongly.
• DNA sequencing - determination of the
nucleotide content of a DNA segment by dye
terminator or dye primer sequencing chemistries.
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1.6.1. Plasmids
Plasmids are widely used as cloning vehicles.

They are double

stranded circular molecules of DNA which are stably inherited in an
extrachromosomal state. All plasmids contain at least one DNA sequence
that can act as an origin of replication so that they can multiply within the
bacterium independently of the host chromosome.

Plasmids range in size

from approximately 1.0 kb to greater than 250 kb, less than 10 kb being the
most desirable for cloning (Brown, 1986). The number of plasmid molecules
in a single bacterial cell is termed the copy number of the plasmid. A
relatively high copy number is required so large quantities of DNA can be
obtained.

1.6.1.1. Selectable markers
DNA is introduced into the bacterial cells by a process of transformation.
Identification of the transformed cells is yja selectable markers, which are
encoded by the plasmid DNA. The plasmid DNA contains 1 or more genes
which confer a new phenotype to the bacteria that have been successfully
transformed (see Table 1.4. below).

Table 1.4 Phenotypic traits conferred by plasmids

Antibiotic resistance
Antibiotic production
Sugar fermentation
Enterotoxin production
Degradation of aromatic compounds
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The most commonly used markers are those that confer resistance to
ampicillin, kanamycin, tetracycline and chloramphenicol.

An ideal cloning vector should incorporate the following features:
(i) should be of low molecular weight,
(ii) be able to confer readily selectable phenotypic traits on the
host cell.
(iii) contain single sites for a large number of restriction
enzymes.
(Sambrook Mid-. 1989).

1.6.2. Restriction endonucleases:
Restriction endonucleases are enzymes produced by bacteria as a
defence mechanisim against foreign DNA.

These restriction enzymes

recognise specific sequences in DNA and cleave the DNA at that particular
site, known as the recognition site.

This property makes them extremely

useful for cloning. Restriction enzymes may be classified into three groups:
• Type I - not widely used in cloning,
• Type II - widely used in cloning as they cleave at a specific
sequence of nucleotides that are 4, 5 or 6 bases in length to produce
discrete fragments of DNA and
• Type III - not widely used in cloning.
Cutting or digestion of double stranded DNA with restriction enzymes will
result in either blunt-ended fragments wherby the enzyme(s) cuts in the
middle of the sequence or cohesive (sticky) ends, wherby the enzyme
produces staggered cuts so that the resulting fragments have short singlestranded overhangs at each end.

Restriction enzymes with different

recognition sequences may produce the same sticky ends e.g. Bam\-\^ and
BglW.
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1.6.3. Ligation of DNA molecules:
Prior to transformation of bacterial cells, the foreign DNA to be cloned
must first be ligated to the linearised plasmid. This involves the formation of
new bonds between phosphate residues at the 5’-termini of the doublestranded DNA and adjacent 3’-hydroxyl moieties.

The formation of the

bonds is catalysed by DNA ligases, the most common being bacteriophage
T4 DNA ligase.

Several stratagies exist for ligation of DNA fragments to

plasmid vectors, depending on the nature of the termini of the foreign DNA
and the restriction sites in both the foreign and plasmid DNA (Sambrook et
al., 1989).

1.6.4. Transformation of bacterial cells:
Transformation can be described as the uptake of DNA molecules by various
cells. Many strains of bacteria have the ability to take up DNA molecules
under certain conditions. Treatment with ice cold calcium chloride followed
by brief heating induces a transient state of ‘competence’ in the bacterial
cells which allows them to take up the DNA fragment.

High voltage

electroporation also induces a competant state in cells, permitting uptake of
foreign DNA.
Transformation of bacterial cells is a relatively inefficient procedure so great
care must be taken in the preparation and handling of the cells to achieve
maximum transformation efficiency.
A number of methods have been developed to identify colonies that contain
the recombinant molecule. These include:
• Restriction analysis of plasmid DNA
• a-complimentation
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• Insertional inactivation
• Screening by hybridisation.

1.6.5. Protein expression in E. coli:
A variety of expression vectors have been developed for the production of
proteins of limited availability in both prokaryotic and eukaryotic systems.
Synthesis of such a protein depends on a number of factors such as
transcription of the appropriate gene, efficient mRNA translation and posttranslational modifications of the polypeptide.
The most commonly used vectors are those derived from the pET,
pGEX and pMAL series (Williams Mai-, 1995). The choice of vector varies
with each application and largely depends on the solubility of the protein of
interest. The cDNA sequence which codes for the desired protein must be
cloned in the correct translational reading frame to ensure the gene is under
the control of the selected E. coli promoter.
A number of factors effect the expression of cloned genes in E coli (see
Table 1.5. below)

Table 1.5. Factors affecting the expression of cloned genes
Promoter strength
Translational initiation sequences
Codon choice
Secondary structure of mRNA
Transcriptional termination
Plasmid copy number
Plasmid stability
Host cell physiology
(adapted from Old R.W. & Primrose S.B. 1995)
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Induction of protein expression in competent cells is \Aa the addition of 0.21.0 M IPTG stock solution to a final concentraion of 0.4-1 mM. The protein
expression procedure must be optimised for each recombinant protein
(Williams et af., 1995).

Once the protein has been induced it must be

determined if the product corresponds to the full length protein or is a
degradation product.

SDS-PAGE and Western blot analysis with an

antibody specific to the translated sequence of interest on the vector or to an
epitope on the recombinant protein will determine the integrity of the protein.

1.6.6. Protein purification:
The method of purification will vary depending on the solubility of the
recombinant protein. The purification of soluble protein is best done from a
crude lysate using tagged protein expression vectors (e.g. pTrcHis2 vectors)
or gel electrophoresis for untagged proteins (Grisshammer and Nagai,
1995).

Insoluble protein can be readily purified from the lysate by

centrifugation.

1.7. The Polymerase Chain Reaction
The Polymerase Chain Reaction (PCR) is an in vitro method for the
enzymatic synthesis of DNA fragments of known sequence using two
oligonucleotide primers, specific for sequences on opposite strands of the
DNA duplex, which hybridise to and flank the region of interest on the target
DNA.
Since it's conception by Kary Mullis (Mullis and Faloona, 1987), the
polymerase chain reaction has transformed molecular biology and has now
become a universal technique.

Minute quantities of genomic starting

material can yield microgram quantities of DNA. A repetitive series of cycles
which involves template denaturation, primer annealing and extension of the
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annealed

primers

by

a thermostable

DNA

polymerase

(Taq

DNA

Polymerase), results in the exponential accumulation of the specific DNA
fragment.
One cycle of denaturation, annealing and extension results in the
doubling of the amount of specified fragment, which can then serve as a
template for the next cycle, so that target DNA doubles at every cycle. The
DNA products are then analysed by electrophoresis on polyacrylamide or
agarose gels and ethidium bromide staining (see Fig. 1.6.)
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Figure 1.6. Schematic view of nucleic acid
amplification by PCR
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Extension

1.7.1. Design and optimisation of PCR
The PCR reaction mix simply involves combining oligonucleotide
primers, nucleotides, buffers, Taq DNA polymerase and a template DNA
sample.

However, the experimental conditions under which PCR are

performed are extremely variable and

must be optimised for each

application.

1.7.1.2. The standard PCR reaction.
Standard PCR reactions are generally carried out in a final 50 pi or
100 pi volume reaction. The basic components are 25-50 mM KCI, 10-20
mM Tris-HCI [pH 8.4], 1.5 mM MgCi2, 0.25 mM of each oligonucleotide, 200
pM of each deoxynucleotide triphosphate (dNTP) - dATP, dCTP, dGTP,
dTTP, 2.5 units of Taq DNA polymerase.

Generally, 0.1-1 pg of genomic

DNA is suitable for amplification. The reaction mixture is overlaid with 50 pi
of mineral oil to prevent evaporation of the components. Twenty-five to thirtyfive cycles are performed for amplification with denaturation at 940C for 20
seconds, primer annealing at 55°C for 20 seconds and primer extension at
72^C for appoximately 30 seconds, ending with a final extension at 72^C for
5 minutes. Automation of the cycling process has greatly enhanced the
speed of PCR.

1.7.1.3. Primer selection
Primers are typically 20-30 base in length but this will vary according
to the application.

Primers should have a 50-60% GC content, avoiding

stretches of polypurines or polypyrimidines. Primer sequences with notable
secondary structure should also be avoided. Complimentarity at the 3'-ends
must also be avoided as this leads to the formation of a primer-dimer artifact.
Primers may be synthesised which contain 5' extensions or mismatches.
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which can be incorporated into the PCR product and provide a means of
introducing restriction sites, an ATG stop codon, regulatory elements or other
structural features.

1.7.1,4. Tag DNA polymerase
A heat-resistant DNA polymerase, isolated from the thermophillic
bacterium Thermus aquaticus is the enzyme used to catalyse
polymerase chain reaction (Saiki,

1990).

the

This highly specific DNA

polymerase {Taq polymerase) can withstand temperatures of up to 95^0,
and therefore will remain active through a complete set of amplification
cycles. The temperature optimum of the enzyme is 75-800C, allowing high
annealing and extension temperatures. This feature increases the specificity
of the reaction and reduces PCR artefacts.

1.7.1.5. Deoxynucleotide triphosphates
The

deoxynucleotide

triphosphates

are

usually

present

concentration of 20-200 pM each (Innis and Gelfand, 1990).
concentrations may lead to misincorporations by Taq polymerase.

at

a

Higher
Stock

solutions of dNTPs should be aliquoted and stored at -20^0. A working
solution containing 1 mM dNTP is recommended. The stock solution should
have a pH of 7.0.

1.7.1.6. Magnesium concentration
The concentration of magnesium in the PCR can affect primer
annealing, strand dissociation temperatures of template, formation of primerdimer artifacts, enzyme activity and fidelity (Innis and Gelfand., 1990)
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Concentrations may range from 1-5 mM but generally a concentration of 1.5
mM is sufficient (Grange Mil-, 1991).

1.7.2. Cycling parameters
PCR is performed via three steps in a cycle of amplificationdenaturation of double stranded DNA, annealing of primers to dissociated
DNA strands, primer extension and synthesis of new DNA strands in an
automated thermocycler.
Typical denaturation conditions are 90-950C for approximately thirty
seconds. Incomplete denaturation will result in the strands reannealing and
failure of the PCR (Innis and Gelfand, 1990).
Cooling to approximately 40-600C will allow the oligonucleotide
primers to anneal to their complimentary sequences (Saiki et

1990).

Annealing temperatures in the range of 55-720C give the best results.
Extension of the primers with Tag DNA polymerase depends on the
length and concentration of the target sequence and the temperature of the
reaction. Generally, heating to 70-750C is acceptable.

The time taken for

extension varies according to the length of the target sequence but a time of
one minute at 72^C is sufficient for products of up to 2 kb (Innis and Gelfand,
1990).
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Objectives

Experimental Objectives.

The structure of this thesis is divided into three sections:
The first section connpares two commercially available ELISA kits for CD44H.
These assays were assessed and the results discussed.
The second section dealt with the development of an ‘in-house’ ELISA for
CD44H. However, due to the unavailability of standard CD44 antigen, this
could not be achieved in a satisfactory manner.
The third section deals with overcoming the problem of antigen availability
by expressing the protein using recombinant DMA technology.

Materials and Experimental Methods

2. Materials & Experimental Methods
This section is divided into two parts:
2.1.

Materials:

describes the

reagents,

buffers

and

other

required

components in the various methodologies outlined.
2.2. Experimental Methods: provides a detailed description of all the assays
performed, using the reagents outlined in the materials section above.

2.1. Materials
2.1.1. Enzyme Linked Immunosorbent Assay Development:

2.1.1.1. Serum Samples:
All serum samples were obtained from the Mercy Hospital, Cork (Ireland).
Test samples (54) were obtained, comprising a mixture of patient samples
with non-Hodgkin's lymphoma, Hodgkin's Disease and other non-malignant
haematological disorders.
Control samples (20) were also obtained from clinically healthy patients.
All serum samples were aliquoted into 100 pi volumes and stored at -20°C.

2.1.1.2. Monoclonal Antibodies:
• Mouse Monoclonal Antibody to Human Brain Leukocyte Membrane Protein
(CD44)
Clone No.: FI0-44-2
Ig. Class: lgG2a
(Serotec Ltd, Oxford, U.K.)

• Monoclonal Anti-Human CD44 Biotin Conjugate
Clone No.: A3D8
Ig. Class: IgGI
(Sigma Immunochemicals, Dorset, U.K.)
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2.1.1.3. Enzymes
• Alkaline Phosphatase-Streptavidin
Specific Activity: 1229 units/mg conjugate. One unit = 1.0 pmol of
p-nitrophenol liberated from p-nitrophenolphosphate per minute at 37°C.
(Vector Laboratories, CA.)

2.1.1.4. Substrate
• p-Nitrophenolphosphate
2 mg/ml solution prepared in Substrate buffer.
(Fluka Chemika-Biochemika, Dublin, Ireland.)

2.1.1.5. Blocking Agents
• Phosphate Buffered Saline (PBS) containing 0.1% Bovine Serum Albumin
(BSA) and 0.5% Gelatin:
To prepare a 10X solution of PBS, dissolve 10 Dulbecco's PBS tablets
(Oxoid, Hampshire, U.K.) in 1 litre of distilled water. Dilute 10X PBS (one in
ten) to a final volume of 100 mis.
Add 0.5g of powdered gelatin (BDH Chemicals Ltd. Poole, England) and
heat gently to dissolve. When cool, add 1g BSA (Boeringher Mannheim,.,
East Sussex, U.K.).

• 1% Horse Serum:
Carbonate-Bicarbonate buffer containing 1% Horse Serum
Heat Inactivated. (TCS Microbiology, Buckingham, U.K)

• 2 % Caesin (BDH Chemicals Ltd. Poole, England).
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2.1.1.6 buffers:

• Coating Buffer:
0.05 M Carbonate-Bicarbonate buffer, [pH 9.5].
Dissolve 3.36g Sodium Bicarbonate (Avondale Laboratories Ltd., Oxon,
England) and 1.06 g Sodium Carbonate (E Merck, F.R., Germany) in 1 litre of
distilled water. Adjust pH with NaOH or H2SO4 accordingly.

• Incubation Buffer
0.05 M PBS, [pH 7.4]

• Wash Buffer
0.0 5 M PBS containing 0.1% Tween-20 (PBST)

• Substrate Buffer:
0.05 M Sodium Bicarbonate, [pH 9.8] containing 1 mM MgCl2.

2.1.2. Comparison of commercial ELISA kits:

Two commercial ELISA kits for CD44H measurement were evaluated:

1. Enzyme linked immunosorbent assay kit for quantitative detection of
soluble human standard CD44, was supplied by Bender Med Systems,
Research Biologicals and Diagnostics, Vienna, Austria.
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2.

Human

Soluble

CD44H

Immunoassay

kit

for

the

quantitative

determination of human soluble CD44 (sCD44) in cell culture supernatant,
serum and plasma, was obtained from R&D Systems, Abingdon, U.K.

2.1.3. Equipment:

Spectrophotometers:
- Dynatech MR5000/7000 Microplate Reader (Dynatech Laboratories Ltd.,
West Sussex, U.K.)

- Ceres U.V. 900C Scanning Autoreader and Microplate Workstation (AGB
Scientific, Dublin, Ireland)

Nunc Polystyrene Microwell Module strips. F8 Maxisorp
supplied by MedLabs, Dublin, Ireland.

Distilled Water
Distilled water was obtained from a Millipore Milli-U Water Purification
System.

2.1.4. Culture media:

Nutrient agar and nutrient broth were both supplied by Oxoid, U.K.
All media was prepared according to the manufacturers instructions and
autoclaved at 121°C for 15 minutes.
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2.1.5. Culture maintenance:
Cultures were grown on nutrient agar/broth at 37°C. Cultures were stored at
-20°C and -80°C on cryobeads (Technical

Service

Consultants Ltd,

Lancashire, U.K.).

2.1.6. Polymerase Chain Reaction:
2.1.6.1 ■ Reagents for PCR
Lysis Buffer: 10 mM Tris-HCI, [pH 8.3], 50 mM KCI, 0.1% (w/v) Tween-20
made up in distilled H O. The lysis buffer was autoclaved for 15 minutes at
2

121°C.

Taq DMA Polymerase: Taq DMA Polymerase was obtained from Promega
(Madison, Wl.) and was supplied with 10X PCR buffer (500 mM KCI, 100 mM
Tris-HCI [pH 8.3], 1% Triton X-100 and MgCl (molecular biology grade).
2

dNTP mix: 2.5 pi of each stock deoxyribonucleotide (100 mM) was diluted in
190 pi sterile H O. The final concentration of dATP, dCTP, dGTP and dTTP
2

in the working mixture was 1.25 mM each.

2.1.6.2. PCR primers:
To amplify CD44 from the CDM8 and pCR®2.1 cloning vectors, the following
primers were used:

CD44A, {forward primer} 5’-TAGGAGGTCGAGGAAAGCG-3’ [19- mer]
CD44B, (reverse primer) 5’-CAGTAGCACATTGCATCT-3’ [18-mer]
The primers were chosen based on the GenBank sequence data (Accession
number: U40373)
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To amplify CD44 from the pCR-Script™ cloning vector and the expression
vector pTrcHis2, a third primer was used similar to that of CD44B, which
contained a Bgl\\ restriction site at the 3’end of the primer:

CD44C, {reverse primer} 5’-AGATCTCAGTAGCACATTAGATCT-3’
[24-mer]

The annealing temperature for ail primers was set at 57°C. All primers were
aliquoted and stored at -20°C.

2.1.7. Agarose gel electrophoresis:
Agarose gel electrophoresis was carried out in a 1% agarose gel (Promega,
Madison, Wl.) in IX Tris-Borate-EDTA (TBE) buffer containing 35 ng/ml
ethidium bromide.

Electrophoresis was carried out in a Horizon® 58

Horizontal Gel Electrophoresis System (Life Technologies, GibcoBRL, U.K. )
at 80 V. The power supply was provided by a Pharmacia Electrophoresis
Constant Power Supply

Unit ECPS 3000/150

(Pharmacia,

Uppsala,

Sweden).

2.1.7.1. Buffers for electrophoresis:
10X Tris-Borate-EDTA (TBE) buffer:

90 mM Tris, 90 mM boric acid,
2.5 mM EDTA [pH 8.3].

10X Loading buffer:

6.6 ml glycerol, 3.3 ml 10X TBE,
100 pi of 10% (w/v) bromophenol
blue.
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2.1.7.2. Molecular Weight Markers:
Molecular weight markers were used in order to allow sizing of the products
from the PCR reaction. The DNA molecular weight marker III (bacteriophage
X

digested with EcoRI and H/ndlll) was used as a standard during the

electrophoresis of all samples. DNA Molecular Weight markers III run in the
size range 125 bp to 21.2 kb (see Appendix I)

(Boeringher Mannheim,

Germany).

2.1.8. CD44 cDNA was a generous gift from Dr. Ivan Stamenkovic,
Massachusetts

Cancer

Centre,

Massachusetts

General

Hospital,

Charlestown, MA 02129, USA.

2.1.9. Competent Escherichia coli cells:

• EcM strain MCI061/P3 Stab:
Genotype: F’, araA139. A(araABC-leu)7679galU aalK AlacX74hsdR2
(r’^,m'"‘^) strA deoR"" rpsLthi -1mcrB.{p3:amber amp^amber tet^Km^}.
(Invitrogen B.V., Leek, The Netherlands).

• Epicurian coli®XLI-Blue MRF’ Kan Supercompetent cells:
Genotype: (mcrA)183A(mcrCB-hsdSMR-mrr)176 endAI supE44 thi-1 recAl
gyrA96 relAI lac[F’ proAB lacl^ZAMIS Tn5 (Kan*^)]
(Stratagene Ltd., Dublin 18, Ireland).

• Epicurian coli® BL21(DE3) competent cells:
Genotype: E. cM B F’ dcm ompT hsdS(r g’m q
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')

gal X(DE3)

(Stratagene Ltd., Dublin, Ireland).

• INVaF’ Competent Escherichia coli cells:
Genotype:

F’ end A1 recA1 hsdR17 (r^^.m^') supE44 thi-1 gyrA96 relA1

(l)8QlacZAM15 A(lacZYA-araF)U169 X'
Competent cells should be stored at -80°C and are extremely sensitive to
temperature and mechanical lysis.

2.1.10. Antibiotics:
Antibiotics were added in various concentrations to the nutrient agar and
nutrient

broth.

Germany),

These

Kanamycin

included
(Sigma

Ampicillin

(Boehringher

Immunochemicals,

Dorset,

Mannheim,
U.K.)

and

Tetracycline (Boehringher Mannheim, Germany). The antibiotics were
prepared in sterile distilled water and sterilised by passing through a 0.8 pm^
filter.

The antibiotics were added to the agar/broth solutions after

autoclaving and cooling to a temperature of approximately 50°C

2.1.11. Cloning of CD44:
2.1.11.1. Polishing of PCR Product:
Polishing of the PCR products was carried out using a PCR Polishing kit.
containing 100 U cloned Pfu DNA polymerase, 10X Pfu DNA polymerase
buffer and 10 mM dNTP mix (Stratagene Ltd., Dublin, Ireland.).

2.1.11.2. Ligation and transformation of CD44:
2.1.11.2.1. Transformation of into E. coli MCI 061 cells:
50 mM CaCl2 (BDFI Ltd. Poole, U.K.) was required for the transformation of
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E. coli MC1061 cells.

2.1.11.2.2. Cloning of CD44 into pCR-Script-Amp SK(+) cloning vector:
The pCR-Script™ Amp SK(+) cloning kit (Stratagene Ltd., Dublin, Ireland.)
was used to clone CD44 into the pCR-Script™ Amp SK(+) cloning vector.
The materials supplied include:
- pCR-Script™ Amp SK(+) cloning vector (pre-digested)
- 10 X pCR-Script reaction buffer
- lOmM ATP
- 5 U/pl Srf I restriction enzyme
- 4 U/fil T4 DNA Ligase
- P-Mercaptoethanol
SOB medium (ingredients: 20.Og tryptone, 5g yeast extract, 0.5g NaCI), 10
mis of 1 M MgCl2 and 10 mis 1 M MgS04were also required.

2.1.11.2.3. Cloning of CD44 into pCR2.1 cloning vector:
The Original TA Cloning® Kit (Invitrogen B.V., Leek, The Netherlands) was
used to clone CD44 into the vector pCR® 2.1.
The materials supplied include:
- Linearized pCR® 2.1 Cloning Vector
-10X Ligation buffer
- 100 mM dNTP’s (25 mM of each dNTP)
- T4 DNA Ligase (4.0 Weiss units/|Lil)
- Sterile Water
- Control DNA Template
- p-Mercaptoethanol
- SOC Medium (2% tryptone, 0.5% yeast extract.
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10.0 mM NaCI, 2.5 mM KCL, 10 mM MgCl2-6H20, 20 mM glucose)

Other Materials Required for cloning include:
• 40 mg/ml 5-bromo-4-chloro-3-indoyl-p-D-galactoside (X-Gal)
in dimethylformamide (DMF).
• 100 mM isopropyl-B-D-thiogalactoside (IPTG).
• TE Buffer (10 mM Tris-HCI [pH 7.5], 1 mM EDTA).
• Falcon® 2059 polypropylene tubes

2.1.12. Rapid colony screening procedure:
• Lysis Buffer 1:
- 90 volumes of 0.25% bromophenol blue, 0.25% xylene cyanol,
25% Ficoll type 400.
- 11 volumes of sterile distilled water
- 40 volumes of 0.2M NaOH and 1% SDS (freshly prepared)

• Buffer 2:
- 3 M Potassium acetate and 1.8 M formic acid.

2.1.13. Plasmid Isolation:
All plasmids were isolated using a Wizard™ Minipreps DMA Purification
System (Promega, Madison, Wl.).

This system contained the following

reagents:
• 10 ml Cell Resuspension Solution: 50 mM Tris-HCI, [pH 7.5],
10 mM EDTA, 100 |ig/ml RNase A
• 10 ml Cell Lysis Solution: 0.2M NaOH, 1% SDS.
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• 10 ml Neutralisation Solution: 1.32 M Potassium Acetate, [pH 4.8].
• 50 ml Wizard™ Minipreps DNA Purification Resin
• 50 ml Column Wash Solution: 80 mM Potassium Acetate,
8.3 mM Tris-HCI, [pH7.5], 40 |aM EDTA, 55% Ethanol
• 50 Wizard™ Minicolumns
• Other materials required include 95% ethanol, sterile distilled water,
collection tubes and sterile disposable 2 ml syringes

2.1.14. Restriction endonucleases:
The restriction enzymes used were obtained from Boehringher Mannheim,
Germany. The enzymes used were BamH^ (10 U/pl), Bgl\\ (lOU/pl),
EcoR1(10 U/|Lil), H/ndlll (10 U/pl) and Xba^ (10 U/|liI). The enzymes were
supplied with their own recommended 10X digestion buffers.

2.1.15. Expression of the CD44 protein:
2.1.15.1. Cloning of CD44 into the pCal expression vectors:
The cloning of CD44 into the pCal Expression vectors was done via an
Affinity™ Protein Expression and Purification System (Stratagene Ltd.,
Dublin, Ireland).
The materials supplied include:
- pCal-c vector (1.0 pg/ml)
- Thrombin
- Calmodulin affinity resin (in 20% (v/v) ethanol)
- 100 mM EGTA
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Other materials required for cloning include:
-IPTG
- X-Gal
- p-Mercaptoethanol
- SOB medium
- Calf Intestine Alkaline Phosphatase
- Calf Intestine Alkaline Phosphatase buffer
(500 mM Tris-HCI, [pH 8.0], 1 mM EDTA)
- Falcon® 2059 polypropylene tubes

2.1.15.2. Cloning of CD44 into the pTrcHis2 A. B, and C series of expression
vectors:
2.1.15.2.1. Gel extraction of the CD44 insert:
The CD44 insert was excised from a 1% agarose gel using a QIAquick Gel
Extraction kit (QIAGEN Ltd., West Sussex, U.K.).
The materials included were:
- QIAquick Spin columns
- Buffer QG
- Buffer PE (concentrate)
- Buffer EB
- Collection tubes.
Also required for gel extraction:
- 96-100% Ethanol
- 100% Isopropanol
- 3 M Sodium acetate
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2.1.15.2.2. Cloning into pTrcHis2 series of expression vectors:
CD44 was cloned into the pTrcHis2 series of expression vectors (Invitrogen
B.V., Leek, The Netherlands). Twenty micrograms of each vector pTrcHis2
A, B and C was supplied in lyophilised form and resuspended in 20 |il of
sterile distilled water. The vectors were then stored at -20°C.
A 100 mM solution of IPTG was required for the induction of protein
expression.

2.1.16. Purification of the CD44 protein:
2.1.16.1. The recombinant CD44 protein was purified using the Xpress™
Protein Purification System (Invitrogen B.V., Leek, The Netherlands).

The materials supplied include:
• Native Buffers:
- Native Binding Buffer: 20 mM sodium phosphate, 500 mM
NaCI [pH 7.8].
- Native Wash Buffer: 20 mM sodium phosphate
500 mM NaCI, [pH 5.5].
- Native Wash Buffer: 20 mM sodium phosphate,
500 mM NaCI [pH 6.0].
• 3 M Imidizole Stock Buffer (10X): 500 mM NaCI, 20 mM NaP04
buffer, [pH 6.0]
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• Native-lmidizole Elution Buffers:
The following volumes of Native wash buffer, [pH 6.0] and
3M Imidizole stock buffer, pH [6.0] were combined:
3M Imidizole

Wash buffer

50 mM

0.08 ml

4.92 ml

200 mM

0.33 ml

4.67 ml

350 mM

0.58 ml

4.42 ml

500 mM

0.83 ml

4.17 ml

Also required for protein expression and not supplied by the manufacturer:
• Egg white lysozyme
• Liquid nitrogen
• 0.8 pm^ filter

2.1.16.2. SDS-PAGE of the purified protein:
• Acrylamide - molecular biology grade (Promega, Madison,Wl.)
• bis-Acrylamide - molecular biology grade
(Promega, Madison Wl.)
• Sodium dodecyl Sulphate (SDS), (BDH Chemicals, U.K.).
• Ammonium Persulphate - SigmaUltra (Sigma, Dorset, U.K.).
• N,N,N’,N’ - Tetramethylethylendiamine (TEMED) Electrophoresis
reagent (Sigma, Dorset, U.K.)
• 3X Loading Buffer: 3 ml sterile dH20, 3 ml 100% glycerol, 4 ml
20% SDS, 2 ml 1 M Tris-HCI, [pH6.8], 300 pi 1% bromophenol blue
A Working solution was prepared by combining 950 pi of the loading
buffer with 50 pi p-Mercaptoethanol.
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• Comassie Brilliant Blue Stain: 25 % Ethanol, 10% Acetic Acid,
0.055% G250 stain, 0.027% R250 stain.
• Destaining Solution: 10 % Ethanol, 5 % Acetic Acid.
• 8X Running Buffer: 24.3 g Tris, 111.53 g Glycine, 8.0 g SDS.
• Protein Standards (BDH, Poole, U.K.) (see Appendix I).

2.1.16.3. Western blot of the purified protein:
2.1.17.3.1. Buffers
• Transfer Buffer: 39 mM Glycine, 48 mM Tris base, 0.037% SDS,
20% methanol.
• Tris-Buffered Saline (TBST) containing non-fat milk powder:
5% (w/v) non-fat dried milk powder, 150 mM NaCI, 50 mM Tris-HCI,
[pH 7.5].

2.1.16.3.2. Monoclonal antibodies:
• Anti-His monoclonal antibody to His tag. The Anti-His antibody was
the generous gift from Dr. M. McCaffrey, Dept, of
Biochemistry,University College, Cork, Ireland.

2.1.16.3.3. Detection of recombinant protein:
• ECL™ Western Blotting Protein Detection kit (Amersham Life
Sciences , Buckinghamshire, U.K.). ECL™ Reagent Solutions 1
and 2 are mixed in an equal ratio of 1:1, according to the
manufacturers instructions .

2.1.16.3.4. Other materials required:
• Nitrocellulose Membranes
• Whatmann 3M filter paper
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2.2. Experimental Methods:
2.2.1. Evaluation of Commercial ELISA kits:
2.2.1.1. Evaluation of the BenderMed Systems ELISA for quantitative
detection of soluble human standard CD44:
All reagents were prepared according to the manufacturers instructions.
Samples were diluted 1:60 with sample diluent according to the following
dilution scheme:
10 pi sample + 590 pi sample diluent
The microwell strips coated with monoclonal antibody to human sCD44 were
removed from their aluminium pouch and loaded onto a 96 microwell strip
holder.
The microwell strips were then washed twice with 300 pi wash buffer per
well with thorough aspiration of contents between washes.

After the last

wash, the strips were tapped gently on a paper towel to remove excess wash
buffer.
One hundred microlitres of sample diluent in duplicate were added to the
standard wells.

Standard dilutions were prepared by pipetting 100 pi of

sCD44std standard (8 ng/ml), in duplicate, into wells A1 and A2.

The

contents were mixed by repeated aspiration and double diluted down the
plate to a final concentration of 0.12 ng/ml. The final 100 pi was discarded
from the microwells.

One hundred microlitres of sample diluent then was

added in duplicate, to the blank wells. Eighty microlitres of sample diluent
was added to all sample wells, followed by 20pl of the prediluted sample.
Finally 50pl of the diluted HRP conjugate was added to all wells, the plate
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was sealed and incubated at room temperature for 3 hrs on a rotating
platform at 100 rpm.

Following incubation, the plate cover was then

removed and the wells emptied and washed as before.

One hundred

microlitres of the prepared TMB substrate solution was added to all wells,
including the blank wells. The plate was incubated at room temperature for
about 15 mins, away from direct light. The plate was monitored until the
positive wells were recordable and the reaction was stopped with by adding
100 |il 4M H2SO4 to all wells.

The absorbance was read at 450 nm

spectrophotometrically.

2.2.1.2.

Evaluation

of

the

R&D

Systems

human

soluble

CD44H

immunoassay:
All samples were diluted 1:100 with sample diluent.
serum was reconstituted 1:100 with sample diluent.

Parameter control
The microtitre strips

were removed from the aluminium pouch and placed in a microwell holder.
One hundred microlitres of Standard, control or diluted sample was added to
each well in duplicate.

The plate was sealed and incubated at room

temperature for 90 mins. One hundred microlitres of diluted anti-sCD44HRP conjugate was added to each well with sufficient force to ensure mixing.
The plate was sealed and incubated at room temperature for 30 mins.
The contents of each well were decanted and washed by adding 300 pi of
wash buffer per well. After the final wash, the contents were decanted and
the plate tapped upside-down on a paper towel to remove any remaining
liquid. One hundred microlitres of substrate was added to each well. The
plate was sealed and incubated at room temperature for 30 mins.
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One

hundred microlitres of stop solution was added to each well, in the same
order as the substrate. The absorbances were read at 450 nm (within 30
mins).

2.2.2. Enzyme Linked Immunoassay Development
2.2.2.1. Optimisation of coating antibody concentration:
A series of dilutions of the primary antibody anti-CD44 clone F-10-44-22
(Serotec, Oxford, U.K.) was prepared at the following concentrations: 0.5
pg/ml, 1 pg/ml, 5 pg/ml and 10 pg/ml in 0.1 M carbonate-bicarbonate buffer [
pH 9.5].
The antibody dilutions were coated onto polystyrene microtitre plates
according to figure 2.1 (below)
Figure 2.1. Optimisation of coating antibody concentration.
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The plate was sealed and incubated overnight at 4°C.

Each well was

emptied and washed in triplicate with 300 |il PBS [pH 7.4] and blotted dry.
One hundred microlitres of PBS containing 0.5% gelatin and 0.1% BSA was
added and incubated for 30 mins. A serum sample was selected that gave a
concentration of 200 ng/ml with the commercial ELISA and was double
diluted down the plate in duplicate for each concentration of antibody. The
o

plate was sealed and incubated overnight at 4 C. The plate was washed as
before and a 1 pg/ml solution of anti-CD44-biotin was added to all wells and
incubated for 2 hrs at 37°C. After incubation and washing, 100 \x\ of a 1|LLg/ml
solution of streptavidin-alkaline phosphatase was added to each well and
incubated for 1 hr at 37°C. After washing, 100 pi of 2 mg/ml pNPP solution
was added to all wells and incubated for 30 mins at 37°C. The reaction was
stopped

by

adding

1M

NaOH

and

the

absorbance

read

spectrophotometrically at 405 nm in a Dynatech MR5000 plate reader.

2.2.2.2. Determination of an effective blocking agent:
Various blocking agents were assessed to determine the optimum
agent to prevent non-specific binding (MSB). The blocking agents chosen
were:
(i) PBS-gelatin-BSA
(ii) 1 % Horse serum
(iii) BSA
(iv) Casein
The wells of a microtitre plate were coated with a 1 pg/ml solution of primary
antibody. The plate was sealed and incubated at 4°C overnight. The plate
was washed with PBST. Various blocking agents were added according to
Table 2.1. (below)
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Table 2.1. Determination of an effective blocking agent:
Row no.

Blocking Agent

1

PBS containing 0.5% gelatin and 0.1% BSA

2

1 % Horse serum

3

0.1% BSA

4

All components were diluted in PBST

5

Dilutions were prepared in 0.1% PBST and
washing steps used 0.1% PBST

6

2 % Casein

The remainder of the assay was performed as before (see Section 2.2.2.1.
Materials and Experimental Methods)

2.2.2.3. Determination of the effect of PBST on non-specific binding:
The first four rows of a microtitre plate were coated with a 1 pg/ml
solution of primary antibody.

The ELISA was performed as before (see

Section 2.2.2.1., Materials and Experimental Methods) with the following
exceptions (see Table 2.2):
Table 2.2. Effect of PBST on non-specific binding:
Row

Blocking Solution

Row 1

PBST used for washing and dilutions

Row 2
Row 3

PBST used for dilutions only

76

Row 4

PBS used for washing

2.2.2.4. Assessment of NSB bv streptavidin-alkaline phosphatase:
The recommended dilution of the streptavidin-alkaline phoshatase
was 1/1000. However, this appeared to be contributing to the non-specific
binding in the assay.

Two microtitre plates were prepared with varying

dilutions of streptavidin-alkaline phosphatase:
The fiiM contained 100 pi of streptavidin-alkaline phosphatase per well,
diluted in PBST at the following dilutions: 1/1000, 1/2000, 1/4000, 1/6000,
1/8000 and 1/10000. This plate was incubated at 37°C for 30 mins.
The second plate contained 100 pi of streptavidin-alkaline phosphatase per
well diluted in PBST, with the same dilutions outlined above and this plate
was incubated at 37°C for 1 hr.

2.2.2.5. Determination of the optimum concentration of anti-CD44-biotin:
Again the plate was coated with 1 pg/ml solution of primary antibody.
The plate was incubated overnight at 4°C. The plate was then washed three
times in wash buffer. The standard serum sample was double diluted down
the plate, (in duplicate) and incubated at 37°C for 1 hr and the wells washed
again. A series of dilutions of anti-CD44-biotin were prepared in PBS and
applied to the plate according to Table 2.3 (below).
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Table 2.3. Determination of optimum anti-CD44-biotin concentration:
Row

Anti-CD44-biotin (pg/ml)

1

0.5

2

1.0

3

2.0

4

4.0

The plate was sealed and incubated for 1 hr at 37°C. After 3 washes, 100 pi
of a 1/6000 dilution of streptavidin - alkaline phosphatase was added to
each well and incubated for 1 hr. The absorbances of each well were read
at 405 nm.

2.2.3. Cloning of CD44 Protein.
2.2.3.1. Transformation of MCI 061 E. coli cells with CD44::CDM8
2.2.3.1.1. Selection of relevant colonies for transformation procedure:
The strain E c^ MCI061 was selected for transformation with
CD44::CDM8 containing the CD44 cDNA sequence. Bacteria from an E co\\
stab was dispersed into 250 pi of nutrient broth and was streaked onto
nutrient agar plates containing 40 pg/ml Kanamycin.
kanamycin resistant cells.

This selects for

The plates were then incubated overnight at

37°C. Several kanamycin resistant colonies were spotted onto agar plates
containing 7.5 pg/ml tetracycline, 30 pg/ml ampicillin
kanamycin.

and 40 pg/ml

The positions of the colonies were noted in relation to the

original plate. These plates were incubated overnight at 37°C.
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Colonies

which exhibited resistance to kanamycin and sensitivity to tetracycline and
ampicillin were selected and used to prepare competent cells.

2.2.3.1.2. Transformation of E. coli MC1061 cells with CD44::CDM8:
Ten millilitres of sterile broth were incubated with a selected colony and
grown overnight in a shaking water bath at 37°C.

Another 10 ml of sterile

broth was reinocuiated with the overnight culture and the ceils grown to mid
log phase (O.D. goo = O-^). The cells were then centrifuged. The supernatant
was poured off and the ceil pellet was resuspended in 50% volume of 50
mM calcium chloride.

The suspension was throughly mixed and then

allowed to stand on ice for 1 hr. These cells were then recentrifuged and
again resuspended in 50 % of the original volume in CaCl2. Finally the cells
were returned to ice for 1 hr. One microlitre of CD44::CDM8 was added and
the cells were placed on ice for 20 mins. The cells were heat-shocked in a
45°C water bath for 2.5 mins. Using aseptic techniques, 100 pi of cells were
plated on kanamycin, ampicillin and tetracycline plates.

The plates were

incubated overnight at 37°C. The transformed cells when recovered, were
stored on cryogenic beads at -20°C and at -80°C.

2.2.3.1.3. Isolation of plasmid DNA from E. coli MCI 061 cells:
Plasmid

isolation

were performed using a Wizard™ Minipreps

DNA

Purification system (Promega, Madison, Wl.).
Five millilitres of sterile nutrient broth was inoculated with a cryogenic
bead coated with E. coN MCI061
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cells containing the CD44::CDM8

construct. This was incubated overnight in a 37°C shaking waterbath. After
24 hrs, the cells were centrifuged in a microcentrifuge for 1-2 mins at top
speed. The supernatant was poured off and the tube blotted upside-down to
remove excess liquid.

The cell pellet was resuspended in 200 pi of cell

resuspension solution and vortexed to completely suspend the cells. The
cells were then transferred to a 1.5 ml microcentrifuge tube. Two hundred
microlitres of cell lysis solution was added and the tube mixed by inverting 4
times. The cells were incubated until the cell suspension had cleared. Two
hundred microlitres of neutralisation solution was added and the solution
mixed by inverting 4 times. The bacterial lysate was then centrifuged at
14000 X g in a microcentrifuge for 10 mins at room temperature. The cleared
supernatant was decanted into a new microcentrifuge tube. One millilitre of
Wizard™ minipreps DNA purification resin was added to the supernatant and
mixed by inverting the tube.
prepared.

For each miniprep, one minicolumn was

To do this, the plunger was removed from a 2 ml disposable

syringe and set aside. The minicolumn was attached to the syringe barrel.
The resin/DNA mix was then pipetted into the syringe barrel and the plunger
slowly inserted, pushing the slurry into the minicolumn.

The syringe was

removed from the minicolumn and the plunger detached. The syringe barrel
was reattached and 2 ml of column wash solution was pipetted into the
syringe barrel. The plunger was reinserted and the wash solution gently
pushed through the column. The syringe was completely removed and the
column transferred into a microcentrifuge tube. The column was spun at top
speed for 20 secs to dry the resin. The minicolumn was again transferred to
a new tube and 50 )il of sterile water was loaded onto the column and
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allowed to soak in for 1 min. The minicolumn was spun for a further 20 secs
at top speed in a microcentrifuge to elute the DNA. An aliquot of the purified
plasmid was stored at 4°C and the remainder stored at -20°C.

2.2.3.1.4. Restriction digest of the plasmid DNA:
The isolated CD44::pCDM8 plasmid was subjected to a restriction
digest in order to authenticate the construct.
Restriction enzyme digestion was carried out in a 30 pi volume containing:
16 pi CD44::CDM8 DNA
3 pi restriction buffer (as per manufacturer’s instructions)
10 U restriction enzyme
10 pi sterile distilled water.
The plasmid preparation was digested with EcoRI, HindWl, Xba^ and a
combination of the three (vary volume of dH20 accordingly in the digestion
reaction). Digestion was carried out at 37°C for 1 hr. Visualisation of the
digestion products was by electrophoresis on a 1% agarose gel.

Two

microlitres of loading dye was added to 10 pi of digest and loaded onto the
gel.

2.2.4.

Amplification of CD44 from pCDM8:

2.2.4.1. Extraction of template DNA:
An LB-Amp agar plate was inoculated with the CD44::pCDM8
construct from a cryobead and incubated overnight a 37°C. Two colonies
were selected and suspended in 10 pi of lysis buffer. The cells were heat
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shocked for 5 mins at 99°C and then centrifuged for 2 mins. The supernatant
provided the template DNA for amplification of CD44 by PCR.

2.2.4.2. Polymerase Chain Reaction (PCR):
Amplification was carried out in a 50 |il volume. The reaction contained 25
pmol of each primer, CD44A and CD44B, 5 |il of 10x reaction buffer, 2.5 mM
MgClg 2.5 U Taq DNA polymerase, 200 jiM of each dNTP, the final volume
was adjusted to 50 pi by the addition of sterile dH20.

Two microlitres of

template DNA were added and the reaction overlaid with approximately 50
pi mineral oil. The samples were amplified in a Techne programmable DriBlock PHC-2 (Techne, U.K.) Thermocycler using the following cycling
parameters:

94°C

3 mins

1 cycle

1
94°C

1 min

57°C

1 min

72°C

2 mins

30 cycles

i
72°C

5 mins

1 cycle

2.2.4.3. Agarose gel electrophoresis:
Following amplification, the PCR products are visualised on a 1% agarose
gel solubilised in 1X TBE containing 35 ng/ml EtBr.
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Two microlitres of

loading dye were added to a 10 ^il aliquot from the PCR reaction mixture and
10

|Lil

of this mix was loaded into each well and electrophoresied for 1-1.5 hrs

at 80 V followed by analysis under a U.V. transilluminator.

A permanent

record was obtained using Polaroid Land Camera (Model MP4) on a
Polaroid 667 Professional Coaterless black and white film.

2.2.5. Cloning of CD44 cDNA into pCR-Script Amp SK(-f1 cloning vector:
2.2.5.1. Polishing the purified PCR products:
The following components were added in the order listed below, to a 0.5 ml
microcentrifuge tube:
10 pi of the PCR product amplified from CDM8
1 pi 10 mM dNTP mix
1.3 pi of lOx polishing buffer
1 ml of cloned Pfu DNA polymerase (0.5 U)
The polishing reaction was gently mixed and overlaid with 20 pi of mineral
oil.
The polishing reaction was incubated for 30 mins at 72°C.

2.2.5.2. Ligation of CD44 into pCR-Script Amp SK(+) cloning vector:
The following

components

were

added

microcentrifuge
tube:

1 pi of pCR-Script™ (10 ng/ml)
1 pi of pCR-Script™ lOx reaction buffer
0.5 pi of 10 mM ATP
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in

order to a

0.5

ml

2-4 fxl of the polished PCR product-CD44
1 |il of Sli I restriction enzyme
1 |il T4 DNA ligase
Distilled water to a final volume of 10 pi.
Note: The Srf 1 restriction enzyme is required for ligation into pCR-Script only.
The cloning reaction was mixed gently and incubated for 1 hr at room
temperature, followed by 10 mins at 65°C.

2.2.5.3. Transformation of CD44::pCR-Script into Epicurian Coli XLI-Blue MRF
Kan supercompetent cells:
The competent cells were gently thawed on ice. Forty microlitres of cells were
required per transformation reaction and were pipetted into pre-chilled Falcon
polypropylene tubes. Seven microlitres of p-Mercaptoethanol was added to the
cells to yield a final concentration of 25 mM. The reaction was incubated on ice
for 10 mins, and swirled gently every 2 mins. Two microlitres of the cloning
reaction were added to the cells and mixed slowly. The reaction was returned
to ice for 30 mins. The SOC medium was prepared and equilibrated to 42°C.
The transformation reaction was heat-shocked for 45 secs in a 42°C waterbath,
then returned to ice for 2 mins. Four hundred and fifty microlitres of the SOC
were added to the tube and the reaction incubated for 1 hr in a 37°C shaking
waterbath.
Fifty-, 100- and 150 pi volumes of the transformation reaction was plated onto
separate LB-amp plates and incubated overnight at 37°C.
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2.2.5.4. Amplification of CD44 from pCR-Script Amp SK(+) cloning vector.
A single white colony was selected from the clones containing
CD44/pCR-Script™ and grown up overnight in 500 pi LB-Amp broth.

Two

microlitres of this culture was used for amplification of CD44 from pCR-Script™.
Amplification was performed as previously described (Section 2.2.4.2. Materials
and Experimental Methods) for a total of 30 cycles.

The PCR product was

visualised on a 1% agarose gel.

2.2.6. Amplification of CD44 from pCR-Script using a modified primerCD44C:
CD44C was identical to primer CD44B except that it contains a Bgl ll
restriction site at the 3’ end of the primer.

Amplification conditions were

identical to those previously outlined (see Section 2.2.4.2. Materials and
Experimental Methods)

2.2.7. Protein expression Wathe pCal-c expression vector
2.2.7.1. Restriction digest of the vector pCal-c:
The digest was performed in 30 pi volume containing:
5 pi pCal-c expression vector
24 pi dH20
3 pi Multicore buffer
1 pi Nco^ restriction enzyme
1 pi BamH\ restriction enzyme.
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Digestion was carried out at 37°C for 1 hr, followed by visualisation of the
digestion products on a 1% agarose gel. Two microlitres of loading dye was
added to 10 |il of the digest mix and was subjected to electrophroesis for 11.5 hrs at 80 V.

2.2.7.2. Dephosphorylation of the pCal-c vector:
The vector was dephosphorylated with 0.05 U of fresh calf intestine
alkaline phosphatase (CIAP) added to the remaining digest mixture.
Dephosphorylation was carried out at 37°C for 1 hr.

2.2.7.3. Purification and precipitation of the pCal-c vector:
Fifteen microlitres of phenohchloroform was added to the dephos
phorylated mixture and centifuged for 15 mins. The top layer was removed
and 15 pi chloroform-isoamylalcohol was added.

This was centrifuged for

10 mins, and again the top layer was aspirated into a sterile microcentrifuge
tube, to which 0.2 pi 3 M sodium acetate and 20 pi 100% ethanol were
added. The DNA was precipitated by incubating for 1 hr at -80°C, followed
by centrifugation for 30 ms. The ethanol was decanted and the DNA pellet
allowed to dry overnight. The pellet was then resuspended in 10 pi TE buffer
and allowed to dissolve for 30 mins. The prepared vector was stored at 4°C
until further use.

Ligation, transformation into Epicurian Coli® BL21 (DE3) competent cells
and subsequent PCR amplification were carried out to verify the clone
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construct. All steps were performed as previously outlined for pCR-Script
(see Sections 2.2.5.2-2.2.5.4. Materials and Experimental Methods)

2.2.8. Cloning of CD44 into the pCR2.1 vector.
Prior to ligation with pCR®2.1, the CD44 sequence was first amplified from
pCR-Script™. The PCR differed from previous reactions only in that the
extension step was extended to 7 mins to incorporate a polyA tail on both
ends of the PCR product which allows ligation into pCR®2.1

CD44 was

ligated to the pCR®2.1 vector as described previously (see Section 2.2.5.2.
Materials and Experimental Methods).

Following ligation, CD44::pCR®2.1

was transformed into INVaF’ competent cells.

Plasmid purification and

restriction digest with EcoR1 were subsequently performed, as previously
described (see Section 2.2.3.1.4. Materials and Experimental Methods).

2.2.9. Protein expression via the pTrcHis2 series of vectors:
2.2.9.1. Gel extraction of CD44 insert:
The EcoRI restriction digest fragment from section 2.2.8.2. (Materials
and Experimental Methods) was electrophoresed on a 1% agarose gel for 1
hr at

80 V. The insert was purified from the gel using a QIAGen QIAquick

Gel Extraction kit, following the manufacturers instructions as follows:
The CD44 fragment was excised from the gel with a sterile scalpel and
weighed in a microcentrifuge tube. Three volumes of buffer were added for
every 1 volume of gel.

The tube was incubated at 50°C for 10 mins,

vortexing every 2 mins to help dissolve the gel.
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One gel volume of

isopropanol was added and the reaction mixed. One QIAquick column was
placed in a 2 ml collection tube and the sample was applied to the column
and centrifuged for 1 min. The flow-through was discarded and the column
was returned to the collection tube. 0.75 ml of Buffer PE was added to wash
the column and centrifuged for 1 min. Again, the flow-through was discarded
and the column centrifuged for an additional 1 min. The column was placed
in a clean 1.5 ml microcentrifuge tube and 50 pi of sterile water added and
then centrifuged for 1 min.

2.2.9.2. Ligation of CD44 into the pTrcHis2 vectors A. B.and C:
The pTrcHis2 series of vectors are supplied in three different reading frames
A, B and C which allows the subcloning of an EcoRI digested fragment in
frame into one of the vectors.

2.2.9.2.1. Digestion of the pTrcHis 2 vectors:
Each of the vectors pTrcHis 2 A, B and C was subjected to restriction
digestion with EcoRI. The digest mixture consisted of 2 pi vector, 3 pi buffer
H, 24 pi dH20 and 1 pi EcoRI. The vectors were digested for 1 hr at 37°C.

2.2.9.2.2. Ligation and transformation of CD44 into the pTrcHis2 vectors:
Ligation and transformation into INVaF’ competant cells was performed as
before (see Section 2.2.5.2.-2.2.5.3. Materials and Experimental Methods)
A separate ligation and transformation reaction was performed for each
vector

88

2.2.9.3. Screening for the CD44 insert:
A rapid colony screening procedure was used

to screen for colonies

containing the CD44 insert. A grid template was marked out on an LB- agar
plate, with the sections numbered 1 to 20. Only white colonies from the
transformation plates were selected. Using a sterile pipette tip, a colony was
gently picked up, using a slight sucking action. The tip was touched very
lightly onto the surface of the plate in order to preserve the clone.

The

remainder of the colony was transferred into a microcentrifuge tube
containing either 16 pi (large colonies) or 8 pi (small colonies) of lysis buffer.
The colony was gently resuspended in the buffer without the formation of
bubbles.

Three microlitres of buffer 2 (1.5 pi for small colonies) was

aliquoted onto the wall of the microcentrifuge tube and the tube centrifuged
for 4 mins. This crude sample was loaded onto a 0.8% agarose gel, leaving
a small pellet of debris behind.

The gel was electrophoresised for

approximately 2 hrs at 80V. The DNA was visualised under U.V. light as
before (see Section 2.2.4.3. Materials and Experimental Methods).
Clones found to contain the insert were grown up overnight in 2 mis
LB-Amp broth in a 37°C shaking waterbath.
PCR was performed in order to confirm the presence of the CD44
insert in the pTrcHis 2 vector, using primers CD44A and CD44C.

2.2.10. Induction of protein expression:
Day 1.
Separate LB-Amp plates were inoculated with each clone in order to culture
pure colonies. The plates were incubated overnight at 37°C.
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Day 2.
Two millilitres of LB-Amp broth was inoculated with a single colony and
grown overnight at 37°C.

Day 3.
Ten millilitres of LB-Amp broth was inoculated with 0.2 ml of the overnight
culture. This was incubated in a 37°C waterbath with vigorous shaking until
the culture reached an O.D.qqq of 0.6. This took approximately 4 hrs. Using
aseptic techniques, 1 ml was removed from this culture and was centrifuged
at 30000

X

g for 30 secs. The supernatant was removed and the cell pellet

frozen at -20°C.

This was the zero time point sample.

Nine hundred

microlitres of a 100 mM IPTG stock solution for induction were added and the
culture returned to the shaking waterbath and incubated for another 5 hrs.
Following incubation, the culture was centrifuged and the supernatant
aspirated. The cell pellet was frozen at -20°C.

2.2.11.

Sodium-dodecyl-sulphate

(SDS)-polvacrylamide

electrophoresis (PAGE):
Two glass plates were thoroughly cleaned, dried and assembled
according to the manufacturers instructions.

An 8% resolving gel was

prepared by combining the following components {in order ) in a conical
flask:
11.5 ml dH20,
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6.7 ml 30% acrylamide mix,
6.3 ml 1.5 mM Tris [pH 8.8],
0.245 ml 10% SDS,
0.25 ml 10% ammonium persulphate and
0.015 mis TEMED.
The gel was poured between the glass plates, leaving enough space for the
stacking gel to be poured on top. The gel was overlaid with isobutanol and
allowed to polymerise at room temperature for approximately 40 mins.
Once polymerisation was complete, the isobutanol was poured off
and the excess removed with a paper towel.

The 5% stacking gel was

prepared by combining the following {in order):
2.7 ml dH20,
0.67 ml 30% acrylamide mix,
0.5 ml 1 M Tris-HCI [pH 6.8],
0.04 ml 10% SDS,
0.04 ml ammonium persulphate and
0.004 ml TEMED.
The gel was poured onto the resolving gel immediately and a clean comb
inserted into the stacking gel. This gel was allowed to polymerise at room
temperature for 30 mins.
After polymerisation, the comb was removed and the wells washed
with distilled water to remove unpolymerised acrylamide.

The gel was

installed in the electrophoresis apparatus and immersed in Tris-Glycine
buffer, without the formation of air-bubbles. All samples were denatured by
boiling for 5 mins in Laemmli sample buffer.
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A 5 pi aliquot of rainbow

markers was also denatured along with the sample. Twenty microlitres of
the denatured sample was loaded onto the gel using a Hamilton syringe.
The electrophoresis apparatus was connected to a power supply and run at
200 V for approximately 40 mins. The progress of the protein standard was
monitored throughout.
Once the bromophenol blue had run to the end of the gel the current
was stopped and the glass plates removed from the apparatus. The plates
were gently prised apart and the gel removed. The gel was immersed in a
Commassie Brilliant Blue bath for approximately 4 hrs on a rotating platform.
The gel was then destained overnight in ethanol/acetic acid buffer.

2.2.12. Western blot analysis of the CD44 protein.
2.2.12.1. Transfer of CD44 protein to nitrocellulose filter:
Following SDS-PAGE, 4 pieces of 10 x 8 cm Whatmann filter paper
and 2 pieces of 6 x 8 cm nitro-cellulose sheets were cut out. Both the nitro
cellulose and the filter paper were immersed in transfer buffer.

Sponges

from the blot apparatus were also soaked in the same buffer.

The

electroblotting apparatus was assembled as detailed in fig. 2.2 (below). A
current was applied and run for 4 hrs at 130 V. Following electrotransfer,
both sheets were immersed in blocking buffer for 30 mins.

The blocking

buffer was replaced with fresh buffer and immersion continued for another
30 mins. The sheets were finally blocked overnight in fresh blocking buffer.
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Fig 2.2.

Assembly of Electroblotting Apparatus

+

©

2.2.12.2. Detection of the CD44 protein:
The primary antibody (Anti CD44 F-10-44-22) was diluted 1/1000 with
Tris-buffered saline (TBST). The nitro-cellulose filter was incubated in a
resealable plastic bag containing 0.1 ml of blocking solution per centimetre
of filter and the primary antibody solution.

The bag was sealed and

incubated for 2 hrs at 4°C with gentle agitation on a shaking platform. The
bag was then cut open and the blocking agent and antibody discarded and
the filter washed

3 times for 10 mins each with TBST. The radioactively

labelled secondary anti-His antibody was diluted 1/1000 in TBST containing
non-fat milk powder. The filter was then transferred to a heat-sealable bag
containing 0.1 ml blocking agent and approximately 10"^ cpm of radiolabelled
anti-His antibody and sealed. After 1 hr at room temperature with gentle
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agitation, the bag was opened and the filter quickly transferred to TBST
buffer. The radioactive waste was discarded appropriately.

This filter was

then washed 3 times for 10 mins each in TBST, and the protein visualised
using

an

ECL™

Western

Blotting

Detection

System

(Amersham,

Buckinghamshire, U.K.). The ECL™ solution was applied to the filter for 5
mins. After this the filter was dried and wrapped in cling film, and exposed to
film for 1 min before being developed.

2.2.13. Purification ofCD44 protein
2.2.13.1. Preparation of Probond™ column:
The resin in the column was mixed throughly by gently inverting the
column repeatedly.

The column was clamped in a vertical position and

allowed to settle for 10 mins. The top of the column was removed and the
buffer carefully aspirated.

Seven millilitres of sterile distilled water were

added and the cap replaced. The resin was again resuspended by gentle
inversion. Again, the column was clamped and the resin allowed to settle
completely. A final water wash was carried out once more. Seven millilitres
of native binding buffer were added and the resin resuspended in the buffer.
This was again allowed to settle and the buffer was aspirated. This wash
was repeated twice, after which the column was equilibrated and was now
ready for use.
2.2.13.2. Preparation of native E. coli cell lysate:
The IPTG induction process as outlined previously (see Section
2.2.10 Materials and Experimental Methods) was repeated.
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However, the

volume of the culture was increased to 50 ml. The culture was centrifuged at
5000 X g for 5 mins. The supernatant was aspirated and the cell pellet was
resuspended in 10 ml of native binding buffer.

Egg white lysozyme was

added to a final concentration of 100 pg/ml and the reaction incubated on ice
for 15 mins. The tube was then placed in a beaker and sonicated with 2 or 3
X 10 sec bursts of medium intensity. The lysate was then flash frozen in
liquid nitrogen, followed by rapid thawing at 37°C. Three more freeze-thaw
cycles were performed. Insoluble debris was removed by centrifugation at
3000 X g for 15 mins. The lysate was further cleared by passage through a
0.8 pm syringe filter. The His-tagged protein (i.e. CD44) was bound to the
pre-equilibrated column in batches by resuspending the column with 2x5
ml aliquots of lysate. The column was gently agitated for 10 mins to allow
the first batch to bind the column. The resin was allowed to settle and the
second aliquot added.

2.2.13.3. Elution of the bound CD44:
The column was washed three times with 4 ml of native binding buffer,
pH 7.8. The column was then washed with 4 ml of native binding buffer, pH
6.0, for a total of three washes.

Following this step, the column was then

clamped and the cap broken off the lower end. The protein was eluted by
sequentially

resuspending

the resin

in

increasing

concentrations

of

imidazole native elution buffers, agitating for 5 mins and then separating the
resin from the supernatant, allowing it to settle for 10 mins.
supernatants were then collected for analysis.
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All of the

Results and Discussion

3. Results and Discussion.

3.1. Evaluation of Commercial ELISA Kits:
Two commercial ELISA kits were assessed in order to determine the
most sensitive and effective assay system for measuring CD44 levels in
human sera.
The BenderMed Systems ELISA (BenderMed Systems, Vienna,
Austria) for the quantitative detection of human CD44H in serum was initially
obtained in order to assess the use of CD44 as a prognostic marker in nonHodgkin’s lymphoma. Fifty four test samples and 20 normal samples were
assayed using this method.

However,

during the course of these

measurements, a number of problems were highlighted with this system.
Primarily, the standard curve appeared to suffer from the high dose hook
effect, whereby the top standard gave a lower absorbance

reading

compared with the second standard. This implied that high samples could
not be measured accurately (see Fig. 3.1.). In addition, it resulted in a loss of
linearity at a concentration of approximately 1.8 ng/ml of standard CD44.
Most samples of high concentration would
measurement.

require

dilution

prior to

Furthermore, as no control was supplied with the kit and

none was commercially available, the top standard (4 ng/ml) was diluted to a
concentration of 2 ng/ml and placed at intervals throughout the microtitre
plate, in order to act as a control. This also gave unsatisfactory results with a
mean value of 1.2 ng/ml.

The kit manufacturers (BenderMed Systems,

Vienna, Austria) recommended an incubation time of 15 minutes for the
substrate, before the reaction was stopped. However, after 15 minutes, the
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top

standard

and

high

reading

samples

could

not

be

read

spectrophotometrically. Therefore, the microtitre plate had to be monitored
carefully after substrate incubation before the colour became too strong for
spectrophotometric determination.
The R&D human soluble CD44H

immunoassay system

(R&D

Systems, Abingdon, U.K.) became available some time after the BenderMed
Systems ELISA (outlined above).

This assay appeared to give more

satisfactory results. Fifty four test samples were assayed and the standard
curve assayed in duplicate. The standard curve proved to be linear (see Fig.
3.2.). Again, a sample was randomly selected as an internal control and
placed at intervals throughout the plate. The value of this sample using the
BenderMed Systems ELISA was 200 ng/ml. Using the R&D System ELISA,
the control gave a mean value of 204 ng/ml.

Nevertheless, when a

correlation curve of the commercial ELISA systems was plotted, (see
Fig.3.3.) there was no significant correlation between the two, with a
correlation coefficient of r = 0.05 (perfect positive correlation = 1, perfect
negative correlation = -1, no correlation = 0). This demonstrates that there
was little or no correlation between the two assay systems.

The lack of

correlation between the two systems and the variable results led to the
attempt to develop an ‘in-house’ ELISA for human CD44, which would
incorporate an amplifying system for greater assay sensitivity.
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Figure 3.1.

BenderMed Systems
Standard Curve

Concentration CD44 (ng/ml)
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Figure 3.2.

R&D Systems
Standard Curve
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Figure 3.3.

Correlation of Commercial ELiSA Kits
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3.2. Development of an ‘in-house’ CD44 specific ELISA:
3.2.1. Determination of optimum coating antibody concentration:
The primary coating antibody F-10-44-2 (Serotec, Oxford, U.K.) was
diluted across the plate at concentrations ranging from 0.5-10 ng/ml and
incubated overnight at 4°C. Due to the unavailability of CD44 standard
protein commercially, a serum sample which reproduced well in the
commercial ELISA was used as a standard for the ‘in-house’ assay. This
was not an ideal situation as factors in the serum may interfere with the
assay. Anti-CD44 antibody labelled with biotin was used as a secondary
antibody. Initially, this was used at a concentration of 1 pg/ml. Detection of
the CD44 protein was performed making use of the streptavidin-alkaline
phosphatase

format.

The

streptavidin-alkaline

phosphatase

(Vector

Laboratories, CA.) was used at a dilution of 1/1000 as recommended by the
manufacturer.

Incubation with the substrate allowed colour development

within the wells which were then read spectrophotometrically in a Ceres
900C spectrophtometer (AGB Scientific, Dublin, Ireland).
shown in Table 3.2.1.
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The results are

Table 3.2.1. Optimising anti-CD44 coating antibody concentration:

Concentration of Coating Antibody
Cone. CD44
(ug/ml)

200
100
50
25
12.5
6.25
3.13
Blank

(ug/ml)

1 0

5

1

0.5

0.514
0.451
0.516
0.511
0.555
0.548
0.468
0.453

Abs at 405 nm
0.439
0.491
0.431
0.464
0.515
0.433
0.473
0.472

0.401
0.399
0.371
0.349
0.534
0.482
0.487
0.422

0.298
0.307
0.331
0.379
0.413
0.454
0.424
0.330

As can be seen from the values obtained for the blank readings, there
was high non-specific binding from some component of the assay.

The

standard curve was not linear and high absorbance readings were seen in
all the wells. A number of factors could contribute to the high non-specific
binding including direct binding of the enzyme or antibodies or due to
unknown factors in the serum crosslinking with the polystyrene solid phase.
In order to overcome the non-specific binding, a

blocking agent was

introduced after the coating antibody had been laid down, to block available
sites on the solid phase, preventing other components from binding and
causing an apparently elevated signal.

However, a coating antibody

concentration of 1 pg/ml was selected for subsequent assays until standard
CD44 could be obtained.

102

3.2.2. Identifying an effective blocking agent:
A number of blocking agents are currently in use to counteract non
specific binding. The blocking agents assessed were PBS containing 0.5 %
gelatin and 0.1 % BSA, 1 % Horse serum and 0.1 % BSA. Column 1 on the
microtitre plate was blocked using the PBS-gelatin-BSA cocktail. Column 2
was blocked using 1 % horse serum and column 3 was blocked using 0.1 %
BSA alone.

In column 4, PBST was used as a diluent for the remaining

components of the assay and no other blocking agent was used. In column
5, the assay components were diluted in PBST, which was also used for
washing the wells. Caesin at 2 % was used in column 6 and column 7 acted
as a negative control.
As the results in Table 3.2.2. show, the addition of a blocking agent
significantly decreased the absorbance values in all wells, although a
relatively high signal remains in most wells. PBST alone produced the most
significant reduction in absorbance values, indicating it’s suitability as a
possible blocking agent for this assay.

Table 3.2.2. Analysis of several reagents as effective blocking agent.

PBS - GelBSA

1 % Horse
serum

0.168
0.147
0.158
0.149
0.157
0.180
0.236

0.156
0.157
0.211
0.149
0.175
0.265
0.345

0.1 % BSA

Dilutions in
PBST.

Dil & Wash
in PBST

2% Caesin

0.079
0.085
0.084
0.083
0.081
0.084
0.082

0.122
0.107
0.108
0.09
0.240
0.257
0.213

Absorbance at 405 nm

0.177
0.173
0.193
0.164
0.157
0.198
0.137

0.107
0.083
0.086
0.088
0.084
0.085
0.087
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3.2.3. Determination of the effect of PBST on non-specific binding:
In columns 1 and 2 of the microtitre plate, PBST was used for washing
the plate and as a diluent for the assay components. In columns 3 and 4 of
the plate, the assay components were diluted in PBST and PBS (pH 7.4)
was used to wash the wells. However, these results did not demonstrate any
significant improvement on the previous blocking agents assessed (see
Table 3.2.3), implying that a blocking agent alone is not sufficient to
counteract the non-specific binding in the assay, therefore other assay
variables were investigated.

Table 3.2.3. Determination of the effect of PBST on non-specific binding.
Column 1
0.180
0.300
0.352
0.354
0.434
0.299
0.192

3.2.4.

Assessment

Column 3
Column 2
Absorbance at 405 nm
0.187
0.223
0.247
0.330
0.517
0.273
0.228
0.588
0.634
0.258
0.176
0.340
0.167
0.430

of

non-specific

binding

by

Column 4
0.166
0.273
0.236
0.272
0.248
0.218
0.248

streptavidin-alkaline

phosphatase:
This streptavidin-alkaline

phosphatase

is

most

commonly

used

in

immunohistochemical techniques. The manufacturers (Vector Laboratories,
CA) recommend using the streptavidin-alkaline phosphatase at a dilution of
1/1000 for such techniques. As no data was available on the appropriate
dilution for the use of streptavidin-alkaline phosphatase in ELISA, a dilution
of 1/1000 was selected.

To assess whether or not streptavidin-alkaline
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phosphatase was involved in non-specific binding, two microtitre plates were
coated with varying dilutions of streptavidin-alkaline phosphatase and
incubated for 30 and 60 minutes respectively.

As can be seen in Table

3.2.4.1 and 3.2.4.2. , the 1/1000 dilution was judged too low for use with
ELISA. A dilution of 1/6000 satisfactorily reduces the non-specific binding to
values similar to that of the blank wells, with a mean absorbance of 0.009
nm.

Therefore, 1/6000 is the recommended working dilution, with an

incubation period of 1 hour to maximise antibody binding.
Table 3.2.4. Assessment of non-specific binding by streptavidin-alkaline
phosphatase.
3.2.4.1 Thirty minute incubation time
Dilution of
St.-AP.

A
B
C
D
E
F
G

1/1000

1/2000

0.063
0.036
0.008
0.004
0.009
0.027
0.048

Absor bance (-B ank) at 4 05 nm
0.033
0.017
0.023
0.003
0.043
0.023
0019
0.022
0.012
0.032
0.009
0.017
0.002
0.003
0.001
0.013
0.022
0.006
0.001
0.008
0.017
0.001
0.002
0.024
0.043
0.025
0.005
0.004

1/4000

1/6000

1/8000

1/10000

0.125
0.009
0.003
0.003
0.004
0.005
0.004

3.2.4.2 Sixty minute incubation time
Dilution of
St.-AP
A
B
C

D
E

F
G

1/1000

1/2000

0.179
0.058
0.063
0.048
0.068
0.065
0.068

Absor Dance (- E lank) at 4105 nm
0.099
0.047
0.012
0.021
0.188
0.042
0.014
0.092
0.078
0.055
0.012
0.065
0.073
0.037
0.007
0.024
0.061
0.041
0.005
0.012
0.055
0.037
0.011
0.014
0.077
0.047
0.016
0.015

1/4000
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1/6000

1/8000

1/10000

0.001
0.006
0.021
0.001
0.070
0.009
0.007

3.2.5. Determination of the optimum anti-CD44-biotin concentration:
The assay was performed as before using a 1/6000 dilution of streptavidinalkaline phosphatase.

Different concentrations of anti-CD44-biotin were

assessed for optimisation.

However, the absorbance readings were very

low ranging from 0.02 to 0.08 nm (data not shown), implying that the primary
antibody may not be picking up CD44 in the serum or alternatively, that the
secondary antibody was unable to bind the antigen.
To test these possibilities requires the use of a near-pure CD44
antigen. Despite several approaches to the relevant manufacturers, it was
impossible to obtain this antigen.

Since cloned human CD44 cDNA was

available, it was decided to generate this antigen by recombinant DMA
methods. Thus the focus of this study shifted towards the in vitro expression
of CD44 as a first step in the design of an ‘in-house’ kit method to measure
CD44 antigen levels in human serum. Provision of the assay using careful
quality controlled protocols would offer clinical laboratories an effective
means of detecting and monitoring CD44 levels in the serum of patients with
a variety of carcinomas.
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3.3. Sub-cloning CD44 cDNA from pCDM8 into pCR-Script
3.3.1. Transformation of E.coli MC1061 cells with CD44::CDM8:
Human CD44 cDNA was inserted into pCDM8

an Xba^ site on the

vector. CD44 cDNA codes for a glycoprotein with an apparent molecular
weight of 85-95 kDa. The complete CD44 cDNA is 1,297 bp in length and
contains restriction sites for the endonucleases A/col and BamH^.

The

mammalian expression vector pCDM8 is 4.4 kb in size and carries a ColEI
origin for growth in E. c^ and a supF suppressor mutation for maintenance
in E. coli MCI 061 cells.

The CD44::pCDM8 construct containing CD44 cDNA (see Fig. 3.4.)
was kindly supplied by Dr. I. Stamenkovic, (Massachusetts General Hospital,
MA.) in the vector pCDM8 (Seed, 1987). Prior to transformation with
CD44::pCDM8, the E c^ MCI 061 cells from an E c^ stab were subjected
to a selection procedure to determine which cells could be made competent
(see Section 2.2.3.1.1. Materials and Methods).

Initially, bacteria from the

E c^ stab were grown in broth overnight followed by sub-culture on LBkanamycin agar plates.

The kanamycin resistant colonies were replica-

plated onto LB-ampicillin, tetracycline and kanamycin plates and the
positions of the colonies noted.

Six colonies displayed resistance to

kanamycin and these were sensitive to ampicillin and tetracycline. Two of
these six colonies were selected for transformation with CD44::pCDM8.
pCDM8 contains the supF suppressor tRNA sequence which suppresses
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Fig 3.4.

CD44::pCDM8 Construct
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amber mutations in E cM MC1061/P3 cells after transformation.

This

feature permits selection based on ampicillin and tetracycline resistance.
Following transformation, the plasmid was isolated (see Section 2.2.3.13,
Materials & Methods) and characterized by digestion with EcoRI, HindWl and
Xba^. Neither CD44 nor pCDMS contain restriction sites for EcoR^. H/ndlll
linearised the plasmid and Xba^ excised the complete CD44 insert from
pCDM8 (see Fig. 3.5.).

[Due to the poor quality of the gel a schematic

representation of the results is shown below figure 3.5.

These restriction

digests confirmed the authenticity of the CD44::pCDM8 construct in E. c^
MCI 061 cells and the success of the transformation procedure].

3.3.2. Amplification of complete CD44 cDNA bv PCR
CD44 was amplified from pCDM8 by polymerase chain reaction (PCR) (see
Section 2.2.4.2., Materials and Methods). Initially the reaction was optimised
prior to cloning into subsequent expression vectors (see Fig. 3.6.). Several
reaction

parameters were originally

investigated

including

optimising

annealing temperature(s) and primer concentration(s). The initial PCR used
an annealing temperature of 51 °C.

This temperature proved too low,

yielding non-specific amplified product(s) seen after electrophoresis (see
Fig. 3.7.). In order to eliminate these bands, the annealing temperature was
increased to 60°C and the primer concentration reduced from the initial 25
pmol to 15 pmol. At this annealing temperature there was no amplification,
suggesting that a temperature of 60°C is too stringent. The same PCR was
repeated with an annealing temperature of 55°C and primer concentrations
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of 15 and 25 pmol were assessed. Amplification was significantly improved
at this temperature and the primer concentration set at 25 pmol (see Fig.
3.8.).
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1375 bp

Fig. 3.5.

Agarose gel electrophoresis of a restriction digest
of the CD44::CDM8 construct by EcoR^, HindWl and Xba^
Lane 1:

Digest with EcoRI

Lane 2:

Digest with HindlW

Lane 3:

Digest with Xba^

Lane 4;

Digest with EcoRI ./-//ndlll, Xba^
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Fig 3.6. Cloning Strategy

IPTG Induction of CD44
Protein Expression
Protein Purification

I

Affinity Chromatography to purify
recombinant CD44 protein
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Fig. 3.7.

2
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Agarose gel electrophoresis demonstrating
the optimisation of assay annealing temperature

Lane 1:

Annealing Temperature = 55°C

Lane 2:

Negative control

Lane M:

Molecular Weight Markers III
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Figure. 3.8. Agarose gel electrophoresis of optimisation of
assay primer concentrations at 15 and 25 pmol

Lane 1:

25 pmol [primer]*

Lane 2;

25 pmol [primer]*

Lane 3:

Negative Control

Lane 4:

15 pmol [primer]*

Lane 5:

15 pmol [primer]*

Lane 6:

Negative Control

M
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However, some non-specific DNA bands still remained. Further efforts were
made to eliminate these by adjusting the annealing temperature upward (to
57°C) and the primer concentrations was also adjusted ranging from 7.5-30
pmol (see Fig. 3.9.). The latter annealing temperature was found to be the
optimal with an ideal primer concentration of 25 pmol of each primer. These
conditions gave optimum cDNA amplification and eliminated the smearing
seen at the other concentrations. Finally, this optimised reaction contained
200 umol of each dNTP (i.e. dATP, dCTP, dGTP and dTTP), 2.5 mM MgCl2,
25 pmol each of forward and reverse primers, CD44A and CD44B
respectively, and 2 pi of template DNA (approx. 100 ng) per 50 pi reaction
volume. Amplification was carried out for a total of 30 cycles (as outlined in
Section 2.2.4.2. Materials and Methods). The complete CD44 sequence is
1,297 bp in length and was found to run close to the 1,375 bp marker in a
1% agarose gel (see Fig. 3.10. as indicated by the arrowhead).

3.3.3. Cloning of CD44 into the pCR-Script™ vector

Following the optimization of in vitro amplification conditions for full
length CD44 cDNA from pCDM8, the amplified DNA fragment was now pure
(see Fig.3.10.) and could be subcloned into the vector pCR-Script™. Cloning
of CD44 into pCR-Script™ facilitates sequencing of the cloned insert and
subsequent cloning into the pCal series of expression vectors.

As the

fragment was generated by Taq DNA polymerase, it first had to be polished
in order to generate blunt ends for effective cloning into the pCR-Script™
Amp SK+ cloning vector, since Taq DNA polymerase is known to generate
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3’-end modifications on amplified fragments (Hu, 1993). Following the
polishing of purified PCR product (see 2.2.5.1.. Materials and Methods), the
blunt ended CD44 cDNA was ligated into pCR-Script™ (see Section 2.2.5.2.,
Materials and Methods). This ligation mixture was then transformed into
Epicurian Coli® XLI-Blue MRF' Kan supercompetent cells. To distinguish
clones that contain the foreign inserted DMA from recircularized vector
devoid of insert DMA, transformed cells containing the pCR-Script™::CD44
construct were identified after blue/white colour selection,

using the

chromogenic substrate X-Gal. A number of blue and white colonies were
found on each plate. The blue colonies were negative for the construct (i.e.
no insert).

The white colonies should contain the appropriate construct,

requiring further confirmatory analysis. A single white colony was randomly
selected and grown overnight in LB-Amp broth. The CD44 cDNA sequence
was again amplified for 30 cycles from 2 pi of culture, following the overnight
incubation (see Fig. 3.11.).
Following amplification from pCR-Script™, the CD44 cDNA could be further
subcloned into the pCal expression system. All white colonies should be
screened as some of the white colonies may not have the insert, due to a low
insert to vector ratio. False positives could be eliminated by increasing the
insert to vector ratio, as recircularization of plasmid DNA will occur with a
higher frequency at low concentrations of DNA. Sub-cloning into the pCRScript™ vector permits subsequent

DNA

sequencing,

constraints prohibited this from being carrried out.
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Agarose gel electrophoresis of primer concentration
and annealing temperaure optimisation at 57°C.
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30 pmol primer

Lane 2:

30 pmol primer
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Negative control

Lane 4;

25 pmol primer
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25 pmol primer
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Negative control
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Fig. 3.10.

Agarose gel electrophoresis of the
CD44 gene amplifed from CDM8

Lane No 1:

Negative control

Lane No 2:

CD44 amplified from CDM8

M:

Molecular weight markers III
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Fig. 3.11.

2

M

Agarose gel electophoresis of the CD44 gene
amplified from pCR-Script™

Lane 1:

CD44 amplified from pCR-Script™

Lane 2:

Negative control

M:

Molecular weight markers IN
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3.3.4. Cloning of CD44 into the pCal expression vector series
The pCal expression vectors are derived from the pET-11 series of
vectors. The pCal vectors, pCal-n, pCal-c and pCal-kc permit fusion of a
Calmodulin-Binding Peptide (CBP)-affinity tag to the N- or C-teminus of the
protein sequence of interest.

The pCal-n vector carries the CPB coding

sequence upstream of the multiple cloning site which allows for the fusion of
the CPB affinity tag to the N-terminus of the cloned sequence.

pCal-c and

pCal-kc have the thrombin target CPB tag located 3' to the MCS facilitating
fusion of the affinity tag to the C-terminus of the protein sequence. It was for
the latter reason that the pCal-c vector was chosen, as the functional Nterminal domain of the recombinant protein would remain intact after
cleavage of the CPB tag. In pCal-c, the insert was cloned between the Nco^
and the BamH^ sites in the vector.

(Furthermore, an intrinsic ATG start

codon is located within the 5’-region of the CD44 insert which may be used
to initiate translation of the cloned sequence).

CD44 was amplified using CD44A as the forward primer (as before)
and CD44C as the reverse primer. The latter is modified on the primer 5’end, incorporating a Bgl\\ restriction site.

Upon electrophoresis, a small

amount of smearing was seen indicating the reverse primer needed to be
optimised (see Fig. 3.12.). Decreasing the number of amplification cycles to
20 and employing a primer concentration of 25 pmoles was enough to
reduce the smearing artefact sufficiently (see Fig. 3.13.) Incorporation of the
Bg/ll site in the amplicon permits subsequent digestion with both A/col and
Bg/ll. After purification, the digested amplicon can be directionally-cloned
into the Nco1/BamH1 digested pCal-c vector.

In this way a BamH1/Bg/ll

hybrid site is formed after ligation, which cannot be digested by either
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enzyme. The only legitimate BamH^ site now occurs within the CD44 cDNA
insert.

The pCal-c vector was supplied undigested and required a lengthy
preparation procedure prior to ligation with the CD44 cDNA insert.

The

pCal-c vector was first digested with the restriction enzymes Nco^ and
The vector was dephosphorylated to remove any 5’-phosphate
groups from the linearised plasmid, followed by purification. Initial attempts
at this protocol resulted in the loss of vector DNA, possibly at the purification
stages.

When the vector was eventually recovered, various ligation

stratagies were employed to introduce the PCR amplified CD44 cDNA. The
digested vector and insert were ligated at 4°C overnight, 22°C for 4 hours
and 22°C for 2 hours, followed by transformation into Epicurian Coli® BL21
(DE3) competent cells.

Each of the ligations were transformed into the

super-competent cells, along with pBR322 (a medium copy number plasmid)
as a control. The transformation mixture containing the construct that had
been ligated for 2 hours at 22°C produced a small number of colonies after
24 hours incubation at 37°C. In order to establish the presence of the insert,
a single colony was grown up in broth and incubated overnight at 37°C. Two
microlitres of the broth was used as a template for PCR using primers
CD44A and CD44C. Amplification for 30 cycles failed to produce a PCR
product. Despite numerous attempts at various ligation and transformation
stratagies (data not shown), cloning of the CD44 insert into the pCal-c
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Fig, 3.12.

Agarose gel electrophoresis of the CD44 gene amplified
from pCR-Script™ using modified primers CD44A and CD44C

Lane 1:

CD44 amplified from pCR-Scripr^
using primers CD44A and CD44C

Lane 2:

Negative control

M

Molecular weight markers III

122

3

Fig. 3.13.

4

5

M

Agarose gel electrophoresis of the optimisation of
CD44 amplification from pCR-Script™ for a total of 20
cycles and at primer concentrations 12.5 and 55 pmol.

Lane 1:

25 pmol primer amplified for 20 cycles*

Lane 2:

25 pmol primer amplified for 20 cycles*

Lane 3:

12.5 pmol primer amplified for 20 cycles

Lane 4:

12.5 pmol primer amplified for 20 cycles

Lane 5:

Negative control

M

Molecular weight markers III
In duplicate
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expression vector was not achieved. This is most probably due to instability
of the vector with its subsequent loss at some stage of its preparation, even
though only picogram quantities are required for ligation. The problem did
not appear to lie in the transformation protocol as the control plasmid
pBR322 transformed each time. Plating more of the transformation did not
improve the growth on the test plates.

However,

though CD44 is not

normally toxic, its expression in BL21 (DE3) competent cells may have been
deleterious to the host cells.
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3.3.5. Cloning of CD44 into the pCR2.1 vector
In order to overcome the problems associated with pCal-c, an alter
native approach was undertaken.

CD44 was amplified from pCR-Script™

and ligated into the vector pCR®2.1, using a TA Cloning® kit. This allowed
direct cloning of the PCR product, without the need for fragment preparation.
The pCR®2.1 vector contains T-3’ overhangs which allow direct ligation of
the insert to the vector. (Amplification of the PCR product with Taq DNA
polymerase and increasing the final extension step to 7 minutes generated
A-3’ overhangs on the linear insert).
Following amplification (see Fig. 3.14), CD44 was ligated to pCR®2.1
overnight at 4°C. The construct was then transformed into INVaF’ competent
cells, which allow for clone selection y[a blue/white screening of the
colonies.

A large amount of colonies were seen on the test plate. Only the

white colonies should contain the CD44 insert.

To identify the correct

colonies, a selection of white colonies and 1 blue colony were subjected to a
rapid colony screening procedure.
control (see Fig. 3.15.).

The blue colony acted as a negative

Fourteen white colonies selected appeared to

contain the CD44 insert.
Plasmid purification and restriction digest with EcoRI confirmed the
presence of the CD44 cDNA in the positive white colonies.

Digestion with

EcoRI excises the insert as the complete PCR product (see Fig. 3.16.).
These clones were suitable for cloning into the pTrcHis2 series of
expression vectors.
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Fig 3.14.

Agarose gel electrophoresis of CD44 cDNA
amplified from CD44::pCR-Script™ using primers
CD44A and CD44C, in order to generate A-3’ overhangs
for ligation into pCR2.1

Lane 1:

CD44 amplified from pCR-Script™
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Negative control

M:

Molecular weight markers III
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Fig. 3 .15.

Agarose gel electrophoresis of CD44-positive clones
identified by the rapid colony screening procedure
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Agarose gel electrophoresis demonstrating an
EcoRI restriction digest of clones containing CD44;:pCR2.1
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3.3.6. Protein Expression.
The pTrcHis2 expression vectors are pUC derived expression vectors which
utilise the trp promoter for recombinant protein expression (Egon ^ aj.,
1983).

The lacl^ gene encoding the Lac repressor protein is used to

regulate expression. Protein expression is chemically induced using IPTG
which switches on transcription of the of the cloned insert. In this case the
CD44 insert had to be incorporated into the vector in the correct orientation
downstream of the ATG start codon and upstream of a C-terminal peptide
which encodes the myc epitope and six tandem histidine residues (see
Appendix II). The six histidine residues act as a metal binding site in the
recombinant protein and attach to a resin during affinity purification of the
expressed CD44 protein.
Following electrophoresis, the band corresponding to the CD44 cDNA
fragment was excised from the agarose gel and purified (see Fig. 3.17.). All
3 expression vectors were digested with EcoRI and ligated with the insert
overnight at 14°C, followed by transformation into INVaF’ competent cells.
The vectors are supplied in three different reading frames denoted as A, B
and C. CD44 should only ligate in frame into one of the vectors, for proper
transcription and translation. Upon transformation, substantial growth was
found with all three vectors, indicating that the insert may have ligated to all
three vectors. A rapid colony screening procedure was performed to identify
positive clones (see Fig. 3.18.(a) and (b)). Three clones displayed a distinct
bandshift on the gel (see Fig. 3.18 (b). row 3, lanes 8,9,14), indicating that
CD44 had been cloned into the pTrcHis2C expression vector.
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Fig. 3.17.

Agarose gel electrophoresis of gel-purified CD44
in preparation for ligation into the pTrcHis2
series of expression vectors.

Lane 1:

Gel-purified CD44
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Fig. 3.18.a

Agarose gel electrophoresis of rapid colony screening
procedure to identify clones positive for CD44::pTrcHis2

Row 1
M

Molecular weight markers III

Lanes 1-19; Clones containing pTrcHis2A
Row 2
M

Molecular weight markers III

Lanes 1 - 20: Clones containing pTrcHis2B
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Fig. 3.18.b
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Agarose gel electrophoresis of rapid colony
screening to identify clones positive for CD44::pTrcHis2.

M

Molecular weight markers III

Lanes 1 - 2: Clones containing pTrcHis2B
Lanes 3 - 19: Clones containing pTrcHis2C
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Plasmid DNA was isolated from these clones and digested with EcoR1. If
the insert is present it should be excised upon EcoR1 digestion (see Fig.
3.19.). From the digest, it was unclear whether or not the insert was present.
In an attempt to confirm the presence of the insert, these clones were grown
overnight in broth and 2 pi of each broth was used as a template for PCR
amplification. PCR established the presence of CD44 in each of the three
clones (see Fig. 3.20.). This confirmed that the CD44 cDNA sequence had
indeed been cloned into pTrcHis2C. It was expected that the insert should
have ligated to all three vectors. Previous experiments (data not shown) had
demonstrated ligation of the insert to both the pTrcHis2B and pTrcHis2C
vectors but not to pTrcHis2A. The reasons for discrepancy are not clear.
Induction studies demonstrated the presence of the protein in pTrcHis2C. As
a result, the sub-cloning of the insert into the remaining vectors was not
pursued further.
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Fig. 3.19.
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the plasmid purification and EcoR1 restriction
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Fig. 3.20.

Agarose gel electrophoresis of CD44 cDNA
amplified from pTrcHis2 C using the primer pair
CD44A/CD44B and the pair CD44A/CD44C
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Molecular weight markers III
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3.3.7. Induction of the CD44 protein
A time course assay of bacterial growth was first performed (data not
shown) for each clone in order to determine the optimal time point for protein
induction by IPTG. This was found to be at four - five hours for each clone. A
zero time point sample was collected prior to the addition of IPTG. The zero
time point sample and samples taken 5 hrs post-induction from each of the
individual clones were subjected to SDS-PAGE analysis (see Section
2.2.11. Materials and Experimental Methods).

For each of the induced

clones, a distinct band could be seen just below the 97.4 kDa marker. .This
band was not detected in the uninduced samples. The mature CD44 protein
has a molecular weight of 85-95 kDa, indicating that these bands may
correspond to the recombinant CD44 protein (see Fig. 3.21. lanes 2, 4
and 6 ).

Certain size differences must be allowed for due to possible

differences in the processing of the protein in E. coN and human cells.
Western blot analysis was used to verify the expression of the protein. An
anti-His antibody to the polyhistidine residue of the protein was used to
detect immobilsed CD44 protein. Discrete bands were seen above the 78
kDa marker in the induced clones (see Fig. 3.22. lanes 4,5 and 6) while the
uninduced samples did not display these bands (see Fig. 3.22. lanes 1,2
and 3). These results suggest that the CD44 protein was being expressed in
the pTrcHis2C vector.

136

M

Fig. 3.21. Schematic view of SDS-PAGE analysis of protein expression
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CD44 Protein
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Fig. 3.22.

Western Blot Analysis of CD44
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3.3.8. Purification of the recombinant CD44 protein
The expressed protein was purifed using the Xpress™ Protein
Purification System.

The recombinant protein is separated from host

proteins by an affinity chromatography system.

Separation of the CD44

protein from E coli host proteins was via a ProBond™ column pre-packed
with ProBond™ resin. The polyhistidine residues in the recombinant protein
have an affinity for the resin and will bind to it under certain conditions. The
CD44 protein was eluted from the column under native conditions [pH7.4].
Any host cell proteins with an affinity for the resin at this pH were removed by
washing at pH 6.0.

The protein was eluted in various fractions, yja an

imidazole gradient (see section 2.2.13., Materials and Methods), and the
eluate collected and stored at 4°C.
In order to determine the concentration of protein in the eluate, the fractions
were analysed by a Hitachi 911 analyser. The protein fractions which were
eluted at 350 mM Imidazole were found to have a concentration of 1 mg/L
using the Urinary Protein estimation method. This method is suitable for the
estimation of small concentrations of protein in fluids. The fractions collected
at the three other concentrations of imidazole did not contain any eluted
protein. The amount of protein eluted was quite low which may be due to
one of the following factors e.g. low expression of the protein, insufficient
sample loaded onto the column, high affinity of the His tag on the
recombinant protein for the affinity resin or too stringent washing conditions.
In order to attain the highest possible recovery of recombinant protein, the
purification procedure requires optimisation. Unfortunately, time constraints
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prevented this from being carried out.

Purification of the protein under

denaturing conditions may also enhance the recovery of the recombinant
protein.
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Conclusions and Future Directions

4. Conclusions and Future Directions
4.1. Conclusions
(i) Two commercial ELISA systems for the measurement of CD44 expression
in human serum were assessed. The BenderMed systems assay for CD44
was found to be inadequate, in that the standard curve uniformly suffered
from the high dose effect, requiring the dilution of samples with high levels of
CD44. The R&D Systems assay for CD44 proved to be more reliable with a
relatively linear standard curve. Nevertheless, when a correlation curve of
the assay systems was plotted, there was no significant correlation between
the two (r=0.05).

(ii) Initial steps were taken in the development of an ‘in-house’ ELISA for the
detection of CD44 in human serum.

However, further development was

hampered by the lack of pure CD44 standard antigen.

Despite numerous

request to the relevant manufactures, we were unable to obtain CD44
antigen.

(iii) In an attempt to overcome the unavailability of CD44 protein, the CD44
gene was amplified from CD44 cDNA by PCR and subsequently sub-cloned
into a number of vectors. This allowed for the expression of a recombinant
CD44 protein from an E.coli expression system.

(iv) The expression of the recombinant CD44 protein was confirmed by
SDS-PAGE and Western Blot analysis. The recombinant protein was then
affinity-purified and quantified in a Hitachi 911 analyser.
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4.2. Future Directions

(i) Sub-cloning of the CD44 protein into the pCR-Script™ vector permits DNA
sequencing analysis in an ABI Prism™ 310 Genetic Analyser.

(ii) The expression and purification of the recombinant protein may be scaled
up in order to produce unlimited quantities of recombinant CD44 protein.

(iii) The recombinant CD44 protein

may be utilised

in the further

development of an ELISA system for the detection of CD44 in human serum.
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Appendices

Appendix i

Boehrinaer Mannheim markers:

Fragment

No. of base pairs

1

21226

2

5148, 4973

3

4268

4

3530

5

2027

6

1904

7

1584

8

1375

9

947

10

831

11

564

BDH Protein Standards

Fragment

Mole. Wt.

1

222,000

2

97,400

3

66,000

4

30,000

5

21,500

6

14,300

Appendix II
A map of the pCR-Script™ Amp SK(+) vector and the sequence of the
multiple cloning site are shown below. The position at which the PCR
product is ligated into the vector is indicated.

Ssp I 2850

SsdI19
Nae I 330

Xmn I 2645
Sea I 2526

Pvul500
Pwill 529

Pvul2416

/Cpnl657
Srfl 728
Sac I 759

.

T3t

Pvu II 977

AfJ\\\ 1153

T3 prtiier

Reverse priner

5' AATTAACCCTCACTAAAGGG 3'

5' GfiAAACAaTATGACCATG 3'

I

•16
(I-Galactosldise-^

792

fispioei

WfClI

6330109 1

Arl
OtiII
foAV mnlUl
SslI Xfv I
Apt I
tin I
AATTCGATATCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCCfCC IAI AG I OTTCGT^TTOGCGCGCTCACTGGCCGTCGTTTTACAA 3
crTATAr.TTff.AA.AftrTATecrAfifT6&At;<:Tr,rfrfff<;f.fiffATr.flr.TTAAf^.fifiATATCACTCAGCATAATfcCGCGCGAGTGACC6GCAGCAAAATGTT 5
^
◄- +1 T7 promoter

3' CTATGGCAGCTGGAGCT 5'
KS Primer

3' CGGGATATCACraGCATAATG S'
T7 Primer

3' T6ACCGGCAGCAAAATG S'
M13-20 Primer

f(

A map of the pCR® 2.1 vector and the sequence of the multiple cloning site
are shown below. The position at which the PCR product is ligated into the
vector is indicated.

facZaATG
5^,
Ml3 Reverse Primer I
I
I
I I
I
CACi GAA ACA GCT ATG ACjC ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG G^T CCA CTA

crrc err

tgt cgajtactggtac taa tgc ggt tcg aac cat ggc tcg agc cta ggt gat

esOCI EcoRI

EcoRI
I
A <XC GAA TTC TGC
TT CGG CTT AAG ACG

GTA AOG ax GCC AGT GTG CTG GAA TTC GOC TT
CAT TOC COG COG TCA CAC GAC CTT AAG CCG
Aval
PeeRTI
EcoRV
BsO(.\
Noti
Xho\
NsilXbai
Apai
AGA TAT CCA TCA olc TGG OGG CCG CTC GAG CAT GCA TCT AGA 033 CCC AAT TOG CCC TAT
TCT ATA GGT AGT GTG ACC GCC G3C GAG CTC GTA OGT AGA TCT.OCC Q3G TTA AGC OGG ATA

A map of the pCal-c vector and the sequence of the multiple cloning site are
shown below. The position at which the PCR product is ligated into the
vector is indicated.

(pET-11 plasmid vector, /acW
ColEI oriein

Amj/
(pET-11 plasmid vector,
origin)

Thrombin Target

-M I^S

MTfiGOOHfit

4iTr Y

P

«IG

*

*

^QjJfiu^TA^rGACTGGTGGACAGCAAATGGGTCGCPWTOMfiTATCCACcIrGGGAAnigrAWAAGCGACGA

^ fJn INhe I

I

Cutting
Site
CutUngSHe

•

Calnvxluiin-Binding Unit
Wk

KNriAVSAANRFKKISSSG'A

L~1

TCGAAAAACAATTTCATAGCCGTCTCAGCAGCCAACCGCTTTAAGAAAATCTCATCCTCCGGGGCACTTjrGATCC

A map of the pTrcHis2 series of expression vectors and the sequence of the
multiple cloning sites are shown below. The position at which the insert is
ligated into the vectors is indicated.
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